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ABSTRACT 
Protein sequence space has been augmented by researchers wanting to expand the diversity 
of chemical functionalities that can exist within proteins.  Artificial amino acids can range 
from simple atom substitutions such as fluorination, to installation of reactive handles like 
azides and alkynes.  Researchers build upon the framework of natural proteins and have 
developed methods of installing a wide variety of artificial amino acids into proteins.  
Chapter 1 discusses in detail the two methods for metabolic incorporation of unnatural 
amino acids: site-specific incorporation and residue-specific incorporation.  Advantages 
and disadvantages to each method are detailed as well as applications of these methods to 
the examination of problems in chemical biology. 
Non-canonical amino acids analogues that are structurally similar to their canonical 
counterparts can be recognized by the endogenous translational machinery for residue-
specific incorporation.  Chapter 2 describes the directed evolution of the methionyl-tRNA 
synthetase (MetRS) to incorporate propargylglycine, an alkyne analogue that is not 
recognized by the wild-type MetRS.  A new MetRS variant active towards 
propargylglycine was identified after screening libraries of both active site mutations and 
error-prone PCR mutations.  PraRS is capable of producing proteins where methionine is 
quantitatively replaced by propargylglycine.  PraRS also does not recognize 
azidonorleucine, an azide methionine analogue for which the NLL-MetRS was evolved in 
order to enable cell-specific protein labeling.  A method to identify cellular origins of 
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proteins from two different bacterial strains in co-culture was developed using the NLL-
MetRS and PraRS. 
Chapter 3 illustrates the effects of global incorporation of non-canonical amino acids into 
globular proteins.  Although trifluoroleucine and homoisoleucine have shown to increase 
the thermostability of model proteins, incorporation into more chloramphenicol 
acetyltransferase (CAT) does not yield the same benefits.  We find that mutations that 
stabilize CAT for fluorinated amino acid incorporation do not protect against 
homoisoleucine incorporation. 
Lastly, access to new chemical reactions for protein modification requires synthesis and 
incorporation of new non-canonical amino acid analogues.  Chapter 4 describes the design 
of two new artificial amino acids, S-allyl-homocysteine and 3-furanylalanine, for residue 
specific incorporation without expression of mutant synthetases.  Also, a third amino acid, 
azidomethylphenylalanine, was designed for activation by a previously discovered 
phenylalanine-tRNA synthetase mutant.  Incorporation of these three analogues provides 
chemical handles that are potential reagents for cross metathesis, Diels-Alder 
cycloaddition, and generation of a molecular epitope for binding to synthetic receptors.      
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Metabolic Incorporation of Non-Canonical Amino Acids into 
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Introduction 
Nature has utilized the twenty canonical amino acids and evolution to create a wide variety 
of proteins that are responsible for structure, signaling, and catalysis in all living organisms.  
The proteins that serve all of these functions are a small sampling of the possible protein 
sequence space imaginable.  The need to explore all of sequence space is not a priority for 
nature; evolution is driven by how a protein contributes to the fitness of an organism.  By 
removing protein evolution from a fitness-oriented boundary condition, researchers have 
utilized directed evolution to push proteins beyond what is possible in nature1,2. 
Natural protein sequence space is primarily composed of twenty amino acids with 
functional groups including amines, alcohols, carboxylic acids, and aromatic groups.  
Although the combination of these amino acids is capable of complex catalysis, it pales in 
comparison to that possible with the functional groups that are accessible to synthetic 
chemists.  In order to introduce new chemical groups into proteins, many methods have 
been developed to modify canonical amino acids or append synthetic peptides to natural 
proteins3-6.  However, to truly expand protein sequence space, artificial amino acids should 
be utilized in the production of new proteins.   
The process of synthesizing a protein from its genetic blueprints is an extremely high 
fidelity process7, with error rates in DNA replication greater than 108 (Figure 1.2).   
Researchers have taken advantage of the aminoacylation step to incorporate unnatural 
amino acids into proteins.  Enzymes known as aminoacyl-tRNA synthetases (aaRS) are 
responsible for attaching the correct amino acids to their cognate transfer RNAs (tRNAs); 
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aminoacylated tRNAs are subsequently used during translation to decode mRNA into a 
polypeptide chain.  Since steps downstream of aminoacylation are permissive to changes in 
amino acids, attachment of non-canonical amino acids to tRNAs is the limiting step in 
expanding protein sequence space.  We will focus on two methods that involve the 
aminoacylation of non-canonical amino acids, colloquially known as site-specific 
incorporation and residue specific incorporation.     
Site-Specific Incorporation of Non-Canonical Amino Acids 
Incorporation via site-specific incorporation affords researchers the ability to install non-
canonical amino acids at a preprogrammed location within a protein.  In order to ensure 
correct placement of the non-canonical amino acid, the aaRS and tRNA used must be 
orthogonal to the expression host’s translational machinery.  The aaRS/tRNA pairs used 
commonly come from archebacteria, which reduces the likelihood of charging of E. coli, S. 
cerevisiae, and other higher organisms’ tRNAs8.  Directed evolution is performed on the  
aaRS to enable charging of a wide variety of non-canonical amino acids to amber 
suppressor tRNA9.  Aminoacylated amber suppressor tRNA allows for “read-through” of 
the amber codon; full length proteins are synthesized with an artificial amino acid in place 
of genetically incorporated amber stop codon.   
The ability to genetically encode location of the artificial amino acid without disturbing 
other canonical amino acids enables the protein chemist to examine numerous biological 
questions.  Incorporation of p-azido-phenylalanine (Figure 1.1 [1]) or p-benzoyl-
phenylalanine (Figure 1.1 [2]) site-specifically has been utilized for studying protein 
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interactions; both amino acids are capable of photo-activated crosslinking10-14.  Through the 
use of bio-compatible, bio-orthogonal reactions, site specific attachment of molecules (such 
as sugars or PEG) to proteins can be done to improve their utility as therapeutics15-17. The 
application of site-specific incorporation has extended beyond E.coli, to now include 
yeast18,19, mammalian cell lines20-23, and model organisms C. elegans24 and D. 
melanogaster25.    Greater detail can be found in recent reviews about applications of site-
specific incorporation of artificial amino acids26-29. 
Amber suppression does have some drawbacks, some of which have been addressed to 
increase the versatility of the method.  The primary issue is that proteins are modified to 
include a stop codon at the location where the artificial amino acid is desired.  
Aminoacylated amber suppressor tRNA has to compete with release factor-1 for binding at 
the ribosomal A-site.  If the amber suppressor tRNA binds first, the full length protein is 
synthesized with an artificial amino acid at the desired position.  However, should release 
factor 1 bind first, a truncated polypeptide chain is the translational product30,31.  This 
truncated protein can be responsible for over 80% of the total protein product32, 
significantly reducing protein yields.  Furthermore, incorporation of multiple amino acids 
using amber suppressor compounds the release factor 1 issue.  Engineering of the ribosome 
and knockouts of release factor 1 have helped to improve protein production with amber 
suppression32,33.   
The amber stop codon is one of three stop codons used for translational termination by all 
organisms; in E. coli, the amber stop codon is responsible for the termination of 314 genes.  
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The amber suppressor tRNA cannot discriminate between naturally and genetically 
modified stop codons; a certain percentage of natural proteins will have unnatural amino 
acids appended to the ends of their sequences.  The presence of these additional artificial 
amino acids can complicate study of biological processes; visualization of a desired protein 
through attachment of fluorescent probes will have background due to proteins that 
terminate with amber stop codons.  Engineering of E. coli by the Church Lab aims to solve 
this problem by removing all natural amber stop codons34, freeing the amber codon for use 
as a new sense codon.  However, this work is still ongoing and extension of this method to 
other organisms with larger genomes will be a complex undertaking.      
Residue-Specific Incorporation of Non-Canonical Amino Acids 
Residue-specific incorporation is a global replacement strategy; cognate tRNAs for a 
specific canonical amino acid are instead aminoacylated by aaRS with a non-canonical 
amino acid analogue.  Codons for the canonical amino acid across the transcriptome are 
decoded as the non-canonical amino acid.   The replacement is done in a statistical manner; 
decoding of mRNA is based on the levels of tRNAs aminoacylated with natural and 
unnatural amino acids.  By depleting a canonical amino acid, replacement levels can reach 
quantitative levels; without depletion, replacement levels are based on the activity of the 
aaRS to the non-canonical amino acid analogue. 
Incorporation of many residue-specific amino acid analogues can be performed without 
any genetic modification of the host organism35-37; the endogenous aaRS have enough 
promiscuity activity towards the artificial analogues.  Overexpression of aaRS has 
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facilitated the incorporation of a greater subset of analogues38, but engineering of aaRSs 
has provided researchers with even greater options for non-canonical amino acids in 
protein synthesis.  Tang et al. demonstrated that a single mutation made to the editing site 
of leucyl-tRNA synthetase enables the incorporation of many methionine analogues at 
leucine codons39.  Incorporation of p-azidophenylalanine by a mutant phenylalanine-tRNA 
synthetase allows for the formation of photo-crosslinked protein hydrogels40.  
Fluorescence-Activated Cell Sorting (FACS) screening of methionyl-tRNA synthetase 
libraries has enabled the discovery of variants capable of aminoacylating 
azidonorleucine41,42(Figure 1.1 [3]) and trifluoronorleucine43 (Figure 1.1 [4]).   
In contrast to site-specific methods, the residue-specific approach cannot guarantee the 
exact location for an artificial amino acid, only that it will appear at the codons 
corresponding to the canonical amino acid replaced.  Protein engineering is required to 
change the protein sequence to remove undesired codons.  However, without the need to 
genetically modify the host organism, the residue-specific incorporation of non-canonical 
amino acids has been applied to the study of proteome dynamics.  By adding 
azidohomoalanine (Figure 1.1 [5]) at the same time a stimulus is given to an organism, 
newly synthesized proteins will be metabolically labeled with azides44.  Utilizing the bio-
orthogonal Husigen [3+2] azide-alkyne cycloaddition, the proteins made in response to the 
stimulus can be selectively modified with affinity tags or fluorescent probes.  Bio-
Orthogonal Non-Canonical Amino Acid Tagging (BONCAT) has been used to visualize 
new protein synthesis45-47; determine rates of new protein synthesis48-51; and identify 
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proteins involved in histone turnover, neuronal function, and receptor-initiated protein 
synthesis52-55.     
Synthesis of proteins with multiple artificial amino acids is straightforward with residue-
specific incorporation.  Although control over location of those positions is not possible 
with natural protein sequences, recombinant DNA technology allows for the modification 
of natural sequences or the generation of artificial DNA sequences to tailor proteins with 
desired artificial amino acid locations.  Additionally, multiple artificial amino acids can be 
incorporated if they correspond to different canonical amino acid analogues56,57.  However, 
global replacement of a natural amino acid with an unnatural analogue in proteins can 
negatively impact protein function and structure58. 
In the next few sections, we will explore three topics of non-canonical amino acid 
incorporation in greater detail: engineering new substrate recognition in aminoacyl-tRNA 
synthetases, cell-specific BONCAT, and proteins of novel amino acid compositions. 
Engineering New Synthetase Activity 
For both site-specific and residue-specific methods, the roadblock in the incorporation of 
new amino acids is the generation of aaRS activity toward a new substrate.  For artificial 
amino acids that are structural similar to the target aaRS, such as homopropargylglycine 
and methionyl-tRNA synthetase59, incorporation can be performed without any 
modification of the aminoacyl-tRNA synthetase.  To expand chemical functionality 
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available to protein sequence space, novel amino acids can deviate far from their natural 
analogues, requiring engineering of aaRS.  
Evolution of aminoacyl-tRNA synthetases for site-specific incorporation of artificial amino 
acids takes advantage of release factor 1 for selection purposes (Figure 1.3a).  To enrich 
aaRS variants capable of charging a desired artificial amino acid to amber suppressor 
tRNA, a protein that is vital for organism fitness (ex. an antibiotic resistance gene) is 
modified with an internal amber codon.  Since the artificial amino acid is incorporated only 
once, there is less concern that the protein will be destabilized.  Without competition by the 
aminoacylated amber suppressor tRNA, release factor 1 causes the vital protein to be 
truncated and cells harboring that poorly active aaRS variant are selected against.  
However, the possibility still exists where a canonical amino acid is charged to the amber 
suppressor tRNA.  To select against that scenario, the enriched library is transferred to a 
strain where a protein that is harmful to the organism (ex. a DNA or RNA nuclease) now 
contains the internal amber codon.   When this library is expressed in this strain without the 
addition of the artificial amino acid, variants that charge natural amino acids are selected 
again.  Repeated rounds of positive and negative selection allows large libraries to be 
distilled to variants that are specific to the desired artificial amino acid and orthogonal to 
the endogenous translational machinery. 
Since incorporation of non-canonical amino acids in a residue-specific manner can occur at 
multiple locations, different high throughput screening methods were developed to 
circumvent the possibility of reporter gene destabilization.  The incorporation of amino 
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acids with bio-orthogonal reactions provides a means to monitor aaRS activity.  Link et al. 
devised a means to increase cell surface presentation of azides through overexpression of 
an outer membrane protein60 (Figure 1.3b).  Attachment of fluorescent probes to the cell 
surface through copper-catalyzed, azide-alkyne click chemistry or strain-promoted, copper-
free cyclooctyne probes created a means to correlate aaRS activity to cell-surface 
fluorescence.  Active site libraries of the methionyl-tRNA synthetase (MetRS) could be 
screened using FACS to acquire a variant highly active for azidonorleucine. 
Screening for aaRS activity for amino acids without a bio-orthogonal reaction is not as 
straightforward.  Yoo et al. developed a fluorescent protein reporter for MetRS activity 
based on green fluorescent protein (GFP)43.  Methionine positions in GFP that were crucial 
to protein folding were relocated to unstructured regions of the protein, creating a new 
fluorescent protein GFPrmAM.  Incorporation of non-canonical amino acid analogues into 
GFPrmAM does not knock out fluorescence, unlike the case for the wild-type GFP.  Using 
methionine auxotrophs and media depletion of methionine, metRS activity towards non-
canonical amino acid analogues controls the rate of new GFPrmAM synthesis.  Since 
fluorescence is linked to synthetase activity, libraries of MetRS variants can now be 
screened, allowing for the discovery of a mutant metRS for trifluoronorleucine.  However, 
to screen other synthetases in this manner would involve the generation of multiple 
fluorescent reporters similar to GFPrmAM. 
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Mutant aaRSs Enable BONCAT on Subpopulations of Complex Cellular Mixtures  
The benefit of using azidohomoalanine or homopropargylglycine (Figure 1.1 [6]) for 
BONCAT is that the endogenous translational machinery for the organism, whether E. coli, 
yeast, worms, or mammalian cells lines, does not need to be perturbed.  In a non-laboratory 
setting, organisms are rarely isolated from one another, so the need for chemical tools to 
identify and enrich proteins out of a single species is highly desired.  Azidonorleucine can 
be added to complex mixtures of cells and the proteomes will remain unlabeled because 
azidonorleucine is not recognized by the endogenous MetRS.  By constraining the 
expression of the NLL-MetRS61 to a specific cell strain, changes in a particular proteome 
could be explored with BONCAT without interference from other proteins from other 
strains.  Ngo et al. demonstrated that fluorescent probes could be attached specifically to 
the proteome of an E. coli strain containing the NLL-MetRS co-cultured with human 
macrophages62 (Figure 1.4); this is remarkable considering the proteome of the 
macrophages is significantly larger than that of E. coli63. 
The ability to confine protein labeling with azidonorleucine in a spatial manner can also 
apply to organisms of the same species.  Although a single strain of a bacteria has the same 
genotype, environmental conditions can force phenotypic changes which are represented at 
the proteomic level.  By placing the NLL-MetRS under the control of promoters associated 
with a certain phenotype, the proteome of a particular cellular state can be metabolically 
labeled with azidonorleucine64.   
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Being able to control residue-specific incorporation in a spatial and temporal manner, 
BONCAT is being used to identify proteomic responses to a variety of stimuli.  The Tirrell 
Lab is currently applying the use of the NLL-MetRS and mutant PheRS to the study of 
bacterial secretion systems, biofilms, quorum sensing, and examining protein expression in 
specific cells in multicellular organisms such as C. elegans.   
Proteins of Novel Compositions 
The fluorinated region of artificial protein sequence space has been explored extensively in 
the hope that it will provide protein engineers the same benefits it has provided polymer 
chemists, especially increased hydrophobicity, thermostability, and chemical denaturant 
stability.  The replacement of hydrophobic amino acids like leucine, valine, and isoleucine 
with their fluorinated non-canonical amino acid counterparts has provided mixed results.   
Proteins designed by nature with well-defined interactions of leucine residues have showed 
remarkable increases in protein stability after replacement with fluorinated leucine 
analogues.  Leucine zippers are alpha helical proteins with leucine residues at regular 
intervals, making one face of the alpha helix rich with leucine side chains.  A single protein 
is not very stable, but the leucine zippers improve their stability by forming bundles that 
sequester the hydrophobic side chains.  Residue-specific incorporation of trifluoroleucine 
(Figure 1.1 [7]) into various leucine zippers results in significant increase in 
thermostability, raising melting temperatures by 13oC65,66 (Figure 1.5).  The use of 
hexafluoroleucine (Figure 1.1 [8]) in place of leucine also shows significant enhancement 
of leucine zipper thermostability, with upwards of 22oC increase in melting 
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temperatures67,68.  Bilgicer et al. have shown that the leucine zippers made fluorinated 
amino acids preferentially segregate from leucine zippers made with leucine, showing 
fluorinated surfaces could be potentially used to design specific protein interactions69,70. 
Most globular proteins do not have hydrophobic residues sequestered in the same fashion 
as coiled-coiled proteins; the result of fluorinated amino acid incorporation depends greatly 
on the stability of the protein.  The Budisa Lab has had success in incorporating multiple 
monofluroinated analogues of proline, phenylalanine, and tryptophan without knocking out 
lipase function57.  Their attempts to globally incorporation trifluoroleucine in Annexin V, 
GFP, and Barstar (all greater than 10 kDa) resulted in significantly less than quantitative 
incorporation; proteins with high incorporation levels of trifluoroleucine were not observed 
potentially due to protein misfolding/aggregation71.  Wang et al. showed quantitative 
replacement of the five isoleucine residues of murine interleukin2 with trifluoroisoleucine 
(Figure 1.1 [9]) did not affect the protein’s native function72.   
Directed evolution has been harnessed to restore protein function and stability after 
fluorinated amino acid incorporation.  Wild-type GFP fluorescence is completely knocked 
out after incorporation of trifluoroleucine, requiring multiple rounds of evolution to recover 
lost fluorescent73.  Chloramphenicol acetyltransferase is still active at room temperature 
when expressed with trifluoroleucine, but over 20 fold less thermostable at elevated 
temperatures74.  Two rounds of directed evolution are required to restore thermostability 
back to wild-type, leucine levels.  Considering the fact that most amino acid substitutions in 
natural protein sequence space are deleterious, it is not surprising that global incorporation 
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of an artificial amino acid can be significantly destabilizing.  The goal of the Tirrell Lab is 
to continue exploring non-canonical protein sequence space in conjunction with directed 
evolution to create proteins that prefer artificial amino acids to their natural counterparts. 
Topics Described in This Thesis 
Using synthetic chemistry and engineered aminoacyl-tRNA synthetases, we described the 
expansion of artificial protein sequence space to include new amino acids.  These amino 
acids show potential for introducing new chemistries to researchers using residue-specific 
incorporation, including cross metathesis, Diels-Alder cycloadditions, and host-guest 
chemistry.  The directed evolution of a mutant synthetase for cell-specific incorporation of 
alkyne analogues of methionine lays the groundwork for examining new problems with 
BONCAT.  In combination with the NLL-MetRS, the ability to monitor protein expression 
in two different bacteria strains simultaneously is possible without cross-labeling.  Lastly, 
we examine the effects of quantitative replacement of leucine with homoisoleucine on 
chloramphenicol acetyltransferase. 
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Figure 1.1 
 
Structures of amino acids described in this chapter: 1: p-azidophenylalanine; 2: p-benzoyl-
phenylalanine; 3: azidonorleucine; 4: trifluoronorleucine; 5: azidohomoalanine; 6: 
homopropargylglycine; 7: trifluoroleucine; 8: hexafluoroleucine; 9: 5,5,5-trifluoroisoleucine   
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Figure 1.2
 
Error rates in steps involved during protein synthesis. Aminoacyl-tRNA synthetases participate 
in decoding of the mRNA during translation through the attachment of amino acids to their cognate 
tRNAs.  Aminoacylation is the lowest fidelity step; incorporation of non-canonical amino acids 
takes advantage of promiscuous, endogenous aaRSs or use of engineered aaRSs.  
Reprinted by permission from Macmillan Publishers Ltd: Nature (Roy, H.and Ibba, M. Nature 
2006, 443, 41), Copyright (2006)  
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Figure 1.3 
 
Selection/Screening of active aaRS variants toward artificial amino acids.  A) Selection scheme 
to enrich aaRS for site-specific incorporation of artificial amino acids. B) High-throughput 
screening of aaRS for residue-specific incorporation of azide bearing non-canonical amino acids 
Adapted from from (Chin, J. W., Martin, A. B., King, D. S., Wang, L., Schultz, P. G. Proc. Natl. 
Acad. Sci. USA 2002, 99, 11020; Copyright (2002) National Academy of Sciences, U.S.A) and 
(Tanrikulu, I. C., Schmitt, E., Mechulam, Y., Goddard, W. A., Tirrell, D. A. Proc. Natl. Acad. Sci. 
USA 2009, 106, 15285.) 
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Figure 1.4 
 
Cell-specific labeling of E. coli with azidonorleucine in the presence of human macrophages.  
A)  E. coli and macrophages without the NLL-MetRS are incapable of utilizing azidonorleucine for 
protein synthesis (bottom row).  E. coli cells expressing the NLL-MetRS metabolically incorporate 
azidonorleucine into cellular proteins.  By performing copper-catalyzed, azide-alkyne click 
chemistry with TAMRA-alkyne, E. coli cells become fluorescent while human macrophages do not 
exhibit any fluorescence (top row, right panel).  B)  If azidohomoalanine is used in the place of 
azidonorleucine, E. coli and human macrophages metabolically incorporate azides into cellular 
proteins without any genetic modification.  All cells exhibit fluorescence after click chemistry is 
performed with TAMRA (right panel). 
Reprinted by permission from Macmillan Publishers Ltd: Nature Chemical Biology. (Ngo, J. T., 
Champion, J. A., Mahdavi, A., Tanrikulu, I. C., Beatty, K. E., Connor, R. E., Yoo, T. H., Dieterich, 
D. C., Schuman, E. M., Tirrell, D. A. Nat. Chem. Biol. 2009, 5, 715.), Copyright (2009).  
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Figure 1.5 
 
Thermal Stabilization of leucine zipper GCN4 with trifluoroleucine.  Leucine positions in the 
coiled-colied protein dimer are show as yellow space filling models (left panel).  Incorporation of 
trifluoroleucine at 80% of these positions increases the melting temperature by 13oC as measured by 
circular dichroism spectroscopy (right panel). 
Adapted with permission from (Tang, Y., Ghirlanda, G., Vaidehi, N., Kua, J., Mainz, D. T., 
Goddard, W. A., DeGrado, W. F., Tirrell, D. A. Biochemistry 2001, 40, 2790). Copyright (2001) 
American Chemical Society.  
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CHAPTER 2 
 
Two-Strain, Cell-selective Protein Labeling in Mixed Bacterial 
Cultures 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced with permission from Truong, F., T. H. Yoo, et al. (2012). "Two-Strain, Cell-Selective 
Protein Labeling in Mixed Bacterial Cultures." Journal of the American Chemical Society 134(20): 
8551-8556.  Copyright 2012; American Chemical Society. 
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Abstract 
Cell-selective metabolic labeling of proteins with non-canonical amino acids enables the 
study of proteomic changes in specified subpopulations of complex multi-cellular systems.  For 
example, azidonorleucine (Anl) and 2-aminooctynoic acid, both of which are activated by an 
engineered methionyl-tRNA synthetase (designated NLL-MetRS), are excluded from proteins made 
in wild-type cells but incorporated readily into proteins made in cells that carry NLL-MetRS. To 
expand the set of tools available for cell-selective metabolic labeling, we sought a MetRS variant 
capable of activating propargylglycine (Pra).  Pra was chosen as the target amino acid because its 
alkynyl side chain can be selectively and efficiently conjugated to azide-functionalized fluorescence 
probes and affinity tags.  Directed evolution, using active-site randomization and error-prone PCR, 
yielded a MetRS variant (designated PraRS) capable of incorporating Pra at near-quantitative levels 
into proteins made in a Met-auxotrophic strain of Escherichia coli cultured in Met-depleted media.  
Proteins made in E. coli strains expressing PraRS were labeled with Pra in Met-supplemented 
media as shown by in-gel fluorescence after conjugation to Cy5-azide.  The combined use of NLL-
MetRS and PraRS enabled differential, cell-selective labeling of marker proteins derived from two 
bacterial strains co-cultured in media supplemented with Met, Anl, and Pra.  Treatment of the 
mixed marker proteins by sequential strain-promoted and copper (I)-catalyzed cycloadditions 
allowed straightforward identification of the cellular origin of each protein.         
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Introduction 
The methionyl-tRNA synthetase (MetRS) of E. coli is promiscuous with respect to activation of 
natural and artificial amino acids under certain conditions.1,2  For example, homopropargylglycine 
(Hpg) and azidohomoalanine (Aha) can be charged to tRNAMet by the wild-type MetRS and 
incorporated into cellular proteins; replacement of methionine (Met, 1) occurs in statistical fashion 
throughout the proteome.  The reactive side chains of Hpg and Aha provide sites for selective 
attachment of affinity tags or fluorescent probes. 3,4 
Bio-orthogonal non-canonical amino acid tagging (BONCAT) uses pulse labeling with reactive 
amino acids to separate newly synthesized cellular proteins from the pre-existing proteome.5,6    
Recent BONCAT experiments have enabled determination of the kinetics of nucleosome turnover,7 
analysis of localized synthesis of proteins critical to axonal maintenance,8 visualization of localized 
protein synthesis regulated by transmembrane receptors,9 in situ fluorescence imaging of new 
protein synthesis in rat hippocampal neurons,10 and labeling of newly synthesized proteins in 
multicellular organisms.11  
Engineering of the MetRS binding pocket has allowed further expansion of the set of Met analogs 
that can be incorporated into proteins.12-15  Labeling of cellular proteins with azidonorleucine (Anl, 
2) requires expression of the L13N, Y260L, H301L variant of MetRS (NLL-MetRS), which 
activates Anl faster than Met.16  Ngo and coworkers recently reported the use of NLL-MetRS and 
Anl to effect selective, proteome-wide labeling of bacterial proteins made in mixed cultures of E. 
coli cells and mammalian macrophages.16  Hang and coworkers have reported similar studies with 
NLL-MetRS and 2-aminooctynoic acid.15 
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In an effort to expand the set of tools available for cell-specific metabolic labeling of proteins, we 
chose an alkynyl amino acid, propargylglycine (Pra, 3), an amino acid smaller than methionine , 
which is activated slowly or not at all by the wild-type E. coli MetRS.17  Here we describe the 
engineering of a new variant of the E. coli MetRS (designated PraRS) that enables near-quantitative 
replacement of Met by Pra in bacterial proteins.  We also show that Pra can be used as a cell-
specific metabolic label in conjunction with PraRS.  Finally, we report a new method that uses Anl 
and Pra to effect simultaneous, two-strain, cell-specific labeling of bacterial proteins. 
 
Results and Discussion 
Although Pra bears an alkyne group suitable for copper (I)- catalyzed azide-alkyne [3+2] 
cycloaddition, we chose a cell-based screening method that does not require exposure of host cells 
to the copper catalyst.  The screening method used a previously evolved variant of the green 
fluorescent protein (GFPrm_AM) that is nearly insensitive to global replacement of Met by non-
canonical amino acids.13  Because expression of GFPrm_AM in Met-auxotrophic host cells in Met-
depleted medium is limited by charging of tRNAMET, Fluorescence-Activated Cell Sorting (FACS) 
can be used to identify MetRS variants that activate alternative substrates. 
Our initial attempts to evolve MetRS variants for activation of Pra focused on the amino acid 
binding pocket, in which five positions (L13, A256, P257, Y260, and H301) were randomized using 
NNK codons.  Thirteen rounds of positive and negative FACS screening yielded a MetRS variant 
(MO2b_13-2; L13P/A256G/P257T/Y260Q/H301F; Figure 2.2) capable of activating Pra.  
MO2b_13-2 was also found to misincorporate an unidentified amino acid at Met codons (data not 
shown).  A new library (MO9) based on MO2b_13-2 was generated by error-prone PCR to improve 
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specificity for Pra.  Highly active mutants obtained from screening MO9 shared a common trait: 
amino acid changes were localized around the KMSKS motif, a highly conserved sequence that 
plays an important role in stabilizing the aminoacyl adenylate intermediate in the charging of 
tRNA.18,19  In addition, a truncation (E548∆; ∆ is the TGA codon) at the end of the catalytic core of 
MetRS was found to be reversed in some of the most active MetRS variants.20  The C-terminal 
domain of MetRS has been shown to play a role in dimerization of the synthetase and contributes to 
increased tRNA affinity.21  Mutations identified by screening the MO9 library were recombined to 
generate a MetRS variant that we designated PraRS (L13P/A256G/P257T/Y260Q/ 
H301F/A331V/∆548E; Figure 2.2). 
Lysates derived from E. coli strain TYJV2, which carries a plasmid-borne copy of the gene 
encoding PraRS, were treated with tetramethylrhodamine-azide (TAMRA-azide, 4) to confirm 
incorporation of Pra into cellular proteins (Figure 2.3a).  Protein labeling was detected by in-gel 
fluorescence within 5 min of addition of 4 mM Pra to the culture medium.  Although labeling was 
detected in lysates treated with lower concentrations (e.g., 500 µM) of Pra, supplementation at 
higher concentrations increased the incorporation level, as shown by increases in the apparent mass 
of GFPrm_AM due to multi-site conjugation of TAMRA-azide (Figure 2.3b).  Matrix-assisted laser 
desorption ionization mass spectrometry (MALDI-MS) of trypsinized GFPrm_AM expressed in 
Met-depleted M9 minimal medium supplemented with 4 mM Pra confirmed near-quantitative 
incorporation of Pra at positions encoding Met (Figure 2.4).  Lower levels of Met replacement were 
accomplished without depletion of the natural amino acid.  For example, expression of GFPrm_AM 
in M9 medium supplemented with 269 µM Met and 4 mM Pra yielded a protein containing 
approximately a 10:1 ratio of Met to Pra. 
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The use of PraRS for cell-selective proteomic labeling does not require the use of auxotrophic 
bacterial strains.  Prototrophic DH10B E. coli strains harboring plasmid-borne, constitutively 
expressed genes encoding wild-type MetRS, NLL-MetRS, or PraRS were grown to mid-log phase 
and then treated with 1 mM Pra and 269 µM Met for 1 hr..  Cells were lysed and lysates were 
subjected to copper (I)-catalyzed ligation to a Cy5-azide probe (5).   Labeling was detected only in 
lysates derived from cells bearing PraRS (Figure 2.5).  Strains that over-expressed either wild-type 
MetRS or NLL-MetRS showed insignificant levels of proteomic labeling.  Encouraged by the fact 
that Pra is not a substrate for the NLL-MetRS, we sought to develop a method for independently 
labeling the proteomes of two intermixed populations of cells (Figure 6a).  His-tagged marker 
proteins DHFR and GFPm were co-expressed with NLL-MetRS and PraRS respectively, in 
prototrophic DH10B cells.  The two strains were grown separately in M9 medium supplemented 
with all 20 canonical amino acids until OD600 ~ 1 and then mixed together in equal amounts.  The 
mixed culture was then supplemented with 1 mM Anl, 4 mM Pra, and 269 µM Met.  Expression of 
the marker proteins was induced by addition of IPTG.  After 2 hr., His-tagged proteins were 
purified from the mixed culture. 
To prevent cross-coupling of marker proteins derived from different strains, tagging reactions were 
run sequentially (Figure 2.6).  The mixture of DHFR and GFPm was first treated with 
dibenzocyclooctyne-Alexa Fluor 488 (DIBO-Alexa Fluor 488, 6) to tag Anl side chains.  Without 
purification, the mixture was then treated with Cy5-azide under the copper-catalyzed conditions 
required to convert the unstrained alkyne side chains of Pra. In-gel fluorescence scanning showed 
that Alexa Fluor emission was confined to the marker derived from the NLL-MetRS strain, while 
Cy5 labeling was apparent only for the PraRS marker (Figure 2.7). Thus the use of Anl and Pra as 
metabolic labels, combined with the sequential labeling strategy described here, permits confident 
31 
 
 
identification of the cellular origins of proteins derived from mixed cell populations.  Extension of 
this approach to cell-selective proteomic analysis via high-throughput mass spectrometry is 
straightforward.5,15 
 
Conclusions 
A MetRS engineered to use Pra, a small non-canonical amino acid with a reactive side chain, was 
developed to enable differential, cell-selective proteome-wide labeling of two intermixed bacterial 
populations.   The mutations that differentiate PraRS from wild-type MetRS highlight the 
importance of error-prone PCR in the evolution of synthetase variants that activate non-canonical 
amino acid substrates.  Previous efforts in synthetase engineering have focused for the most part on 
the amino acid binding pocket of the enzyme.13,14,22-24  Here we found that mutations adjacent to the 
KMSKS region of MetRS can enhance charging of Pra; these mutations would not have been 
identified without the use of error-prone PCR.  
We and others have shown previously that the use of appropriately-designed amino acids and 
mutant synthetases can enable time-resolved, cell-selective metabolic labeling of proteins.15,16 By 
using the Anl/NLL-MetRS system in conjunction with Pra and PraRS, investigators can now 
interrogate the proteomic responses of two intermixed bacterial strains without crosstalk. Important 
cellular phenomena that would be amenable to study via dual cell-selective labeling would include 
bacterial quorum sensing, the development of biofilms, and interactions among commensal 
bacterial.25-32     
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Materials and Methods 
Materials.   
Restriction enzymes and T4 DNA ligase were purchased from New England Biolabs (Beverly, 
MA).   PfuUltra II Fusion and Mutazyme II were purchased from Agilent Technologies (Santa 
Clara, CA).  DNA oligomers were synthesized by Integrated DNA Technologies (Coralville, IA).  
L-Anl was prepared by previously reported methods.33   Canonical amino acids and L-Pra were 
purchased from Sigma-Aldrich (St. Louis, MO).  His-tag purifications were carried out using 
nickel-nitrilotriacetic acid resin purchased from Qiagen (Valencia, CA).  Sequencing grade trypsin 
was purchased from Promega (Madison, WI). 
Construction of MetRS Libraries.   
Plasmid pMTY11, which contains a MetRS expression cassette, was described previously.13  Active 
site randomization of the MetRS gene was carried out at the L13, A256, P257, Y260, and H301 
positions by site-overlap extension using primers with NNK codons.  PCR products were purified 
on 1% agarose gels.  Fragments containing the randomized positions were assembled and amplified 
using PfuUltra II Fusion DNA polymerase to construct the MetRS library with five randomized 
positions.  The library was re-ligated into pMTY11 using BamHI/NotI restriction sites.  The ligation 
product was transformed into E. coli strain TYJV2 bearing the previously described plasmid 
pQE80L/GFPrm_AM via electroporation.13  
Error-prone PCR mutagenesis of MO2b_13-2 was per-formed with Mutazyme II using primers 
Lib_Fwd (5’-TTCCGACAGCTACGTCGCGGAAC-3’) and Lib_Rev (5’-
GAAGGACCGTAGAAGGTCCTTTAGAG-3’), which flank the MetRS gene.  The target 
mutation rate was two to four mutations per MetRS gene in the library.  The PCR product was 
33 
 
 
purified on a 1% agarose gel and subsequently cloned into pREP4/MO2b_13-2 using the 
BamHI/NotI restriction sites.  The ligation product was transformed into E. coli strain TYJV2 
bearing pQE80L/GFPrm_AM via electroporation.   
 
Screening of MetRS libraries via FACS.   
Met auxotrophic TYJV2 cells containing pQE80L/GFPrm_AM and the MetRS libraries were 
grown at 37oC to mid-log phase (OD600 = 0.8-1.0) in M9 minimal medium (M9 salts, 0.2% 
glucose, 1 mM MgSO4, 0.1 mM CaCl2, 35 mg/L Vitamin B) supplemented with all 20 canonical 
amino acids (each at 40 mg/L), ampicillin (200 mg/L) and kanamycin (35 mg/L).  Upon reaching 
mid-log phase, cells were washed twice with cold 0.9% NaCl and resuspended in M9 minimal 
media supplemented either with 19 amino acids (minus Met) at 40 mg/L or with 19 amino acids 
plus 4 mM Pra.  After 30 min., expression of GFPrm_AM was induced by addition of 1 mM IPTG.  
After 2 hr., cells were washed and resuspended in phosphate buffered saline (pH 7.4) for FACS 
screening. 
FACS screening was performed on a MoFLO XDP cell sorter (Beckman Coulter, Brea, CA) using 
an argon laser (488 nm) and 530/40 nm bandpass filter.  Side scatter was utilized for event 
triggering; forward and side scatter gating was used to remove non-E. coli events.  Event rate was 
maintained between 20000 and 30000 events per second.  Positive sorting to enrich MetRS variants 
specific for Pra involved expression of GFPrm_AM in Pra-supplemented media and collecting the 
0.5-1% of cells characterized by the highest levels of fluorescence.  Negative sorting to remove 
MetRS variants that mischarge canonical amino acids was accomplished by collecting non-
fluorescent cells when GFP was expressed in Met-depleted media.  Cells were sorted into SOC 
medium (2 mL), rescued at 37oC for 1 hr., and further diluted 1:10 with LB medium for overnight 
growth.  Sorted populations were stored at -80oC in 25% glycerol. 
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Pulse Labeling.   
Met auxotrophic DH10B cells containing a constitutively expressed PraRS cassette in the pREP4 
plasmid (pREP4/PraRS) were grown to mid-log phase in M9 minimal medium containing all 20 
canonical amino acids.  Addition of 4 mM Pra to the growth medium was performed without Met 
depletion.  At selected time points, aliquots of cells were removed and chloramphenicol (170 mg/L) 
was added to inhibit further protein synthesis.  Cells were pelleted, lysed, and subjected to copper 
(I)-catalyzed cycloaddition with 25 µM TAMRA-azide, 100 µM CuSO4, 500 µM tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA), and 5000 µM sodium ascorbate as the reducing 
agent.34 After 30 min, each sample was run on a 12% SDS-PAGE gel without purification.  Labeled 
proteins were visualized using a Typhoon Trio (GE Healthcare, Piscataway, NJ) with a 532 nm 
laser and 580/30 nm bandpass filter. 
Mass Spectrometry.   
Expression of GFPrm_AM was carried out in TYJV2 cells transformed with pQE80L/GFPrm_AM 
and pREP4/PraRS.  Cells were grown to mid-log phase and then washed twice with cold 0.9% 
NaCl.  Cells were subsequently resuspended in M9 minimal medium supplemented with 19 amino 
acids (minus Met), 20 amino acids, or 19 amino acids plus 4 mM Pra.  After 30 min., IPTG was 
added to a final concentration of 1 mM to induce expression of GFPrm_AM.  Utilizing the N-
terminal 6 x histidine tag of GFPrm_AM, the protein was purified under denaturing conditions 
according to the manufacturer’s protocol.  Tryptic digests of purified GFPrm_AM were subjected to 
MALDI time-of-flight mass spectrometry with α-cyano-4-hydroxycinnamic acid as matrix.  An 
Applied Biosystems Voyager DE-PRO equipped with a 20-Hz nitrogen laser was used for all 
peptide analyses. 
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In-gel Fluorescence Detection of Two-strain, Cell-selective Protein Labeling.   
Overnight M9 cultures of TYJV2 cells transformed either with pQE80L/GFPm and pREP4/PraRS 
or with the previously described pQE80L/DHFR/NLL-MetRS (pJTN5) and pREP4 were diluted 
1:100 into fresh M9 minimal medium containing all 20 amino acids.16  Cultures were grown to mid-
log phase and equal numbers of cells from each of the two strains were mixed together. After 
mixing, the medium was supplemented with 1 mM L-Anl, 4 mM L-Pra, and 269 µM L-Met.  
Expression of his-tagged DHFR and his-tagged GFPm was induced by addition of 1 mM IPTG for 
2 hr..  DHFR and GFPm were purified on nickel-nitrilotriacetic acid resin according to the 
manufacturer’s protocols under denaturing conditions.   
Sequential labeling of the marker protein mixture was accomplished with DIBO-Alexa Fluor 488 
(Invitrogen, Carlsbad, CA), and Cy5-alkyne (Lumiprobe, Hallandale Beach, FL).  The protein 
mixture (approximately 2 mg/ml) was first treated with 10 µM DIBO-Alexa Fluor 488 in tris-
buffered saline for 1 hr..  Copper (I)-catalyzed cycloaddition was then performed without 
intermediate purification using 25 µM of Cy5-azide, 100 µM CuSO4, 500 µM THPTA, and 5000 
µM sodium ascorbate as the reducing agent.  After 30 min., samples were run on a 12% SDS-
PAGE gel.  Labeled marker proteins were visualized using a Typhoon Trio with a 488 nm laser and 
526 nm shortpass filter as well as a 633 nm laser and 680/30 nm bandpass filter.   
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Figure 2.1 
 
 
Amino acids and fluorescent probes used in this study.  1: Met; 2: Anl; 3: Pra; 4: TAMRA-
azide; 5: Cy5-azide; 6: DIBO-AlexaFluor 488 
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Figure 2.2 
 
 
FACS histograms of E. coli variants obtained from evolution of MetRS for Pra activity.  
Addition of Pra to E. coli cultures in M9 medium supplemented with 19 amino acids (-Met) did 
not change the GFPrm_AM fluorescence of cells expressing endogenous levels of wild-type 
MetRS (compare pREP4-19aa and pREP4-Pra; pREP4 is the vector lacking the MetRS cassette).  
Variant MO2b_13-2 was isolated from the library prepared by randomizing the amino acid 
binding pocket.  MO9c_4-16 was isolated from the error-prone PCR library generated from 
MO2b_13-2, and carries an additional mutation (A331V).  Reverting the stop codon in MO9c_4-
16 to Glu yielded PraRS, which shows the highest fluorescence signal (PraRS-Pra) for cells 
expressed in media supplemented with Pra. 
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Figure 2.3 
 
 
In-gel fluorescence detection of TAMRA-azide after labeling of lysates from Met-
auxotrophic E. coli cells.  a) Time-dependent, proteomic labeling after addition of Pra.  At time = 
0, 4 mM Pra was added to the medium without depletion of Met (269 µM).  Aliquots were 
removed at regular time intervals and chloramphenicol was added to prevent further protein 
synthesis.  Incorporation of Pra into cellular proteins was detected by labeling with TAMRA-
azide within 5 min. of addition of Pra.   
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Figure 2.3 (cont.) 
 
b) The extent of proteomic labeling was dependent on Pra concentration.  Expression of 
GFPrm_AM (top band) was induced after Met depletion and resuspension in medium with and 
without 269 µM Met and various concentrations of Pra.  TAMRA-azide was detected in all lanes 
where Pra was added to the culture medium.  The apparent molecular weight of GFPrm_AM 
increased with increasing amounts of Pra due to higher levels of labeling with TAMRA-azide. 
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Figure 2.4 
 
 
MALDI-TOF spectrum of tryptic digest of purified GFPrm_AM.  His-tagged protein was 
expressed in a Met-auxotrophic strain of E. coli harboring PraRS in medium supplemented with 
19 aa (-Met) plus 4 mM Pra.  Replacement of Met by Pra in the peptide 
HNVMDGSVQLADHYQQNTPIGDGDPVR results in a decrease in mass of 36 Da. 
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Figure 2.5 
 
 
In-gel fluorescence detection of Cy5-azide (top) after labeling of E. coli lysates.  Colloidal 
blue staining (bottom) confirms protein loading in all lanes.  Conjugation of the fluorescent probe 
to cellular proteins requires both expression of PraRS and addition of 1 mM Pra to the medium 
(lane 7).  Over-expression of the wild-type E. coli MetRS (lane 3) confirms the lack of activity 
toward Pra previously reported by Kiick et al.17.   NLL-MetRS also shows little or no evidence of 
activation of Pra (lane 5).  Incorporation of Pra into cellular proteins in the presence of Met is 
confirmed by MALDI-MS (supporting information).  
43 
 
 
Figure 2.6 
 
 
 
Schematic representation of simultaneous, cell-selective metabolic labeling of two proteomes 
in a mixed bacterial culture.  
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Figure 2.7 
 
 
In-gel fluorescence detection of DIBO-Alexa Fluor 488 and Cy5-azide after sequential 
labeling of mixed cell lysates.  Dihydrofolate reductase (DHFR) metabolically labeled with Anl 
was conjugated to DIBO-Alexa Fluor 488 via copper-free, strain-promoted cycloaddition.  GFPm 
metabolically labeled with Pra was conjugated to Cy5-azide by Cu(I)-catalyzed cycloaddition. 
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Effects of Quantitative Homoisoleucine Incorporation on 
Chloramphenicol Acetyltransferase   
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Abstract 
Incorporation of non-canonical amino acids enables access to protein sequence space completely 
unknown to nature; the hope being that these new regions of sequence space will contain improved 
protein stability or catalytic activity.  Chemists have taken advantage of the properties fluorination 
provides polymers: thermal and oxidative stability, hydrophobicity, and inertness to chemical 
reactions.  Protein engineers have utilized fluorinated amino acids successfully in coiled-coiled 
protein interfaces lined by hydrophobic leucine residues, increasing melting temperatures up to 
22oC.  Global incorporation of fluorinated amino acids into globular proteins like chloramphenicol 
acetyltransferase has had the reverse effect, reducing enzyme melting temperature by up to 9oC.  
Fluorinated amino acids have also been limited by incorporation levels, creating proteins that are 
hybrids of natural and unnatural amino acids.  Quantitative incorporation of homoisoleucine, a 
larger aliphatic analogue of leucine, into chloramphenicol acetyltransferase results in decreased 
thermostability.  Mutations that stabilized chloramphenicol acetyltransferase for 80% 
trifluoroleucine incorporation did not increase protein thermostability when 100% homoisoleucine 
was incorporated at leucine positions.   Attempts to recover lost thermostability of the 
homoisoleucine version chloramphenicol acetyltransferase by directed evolution are ongoing.          
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Introduction 
Natural selection has been the driving force for protein evolution over millions of years, probing 
sequence space for beneficial mutations to improve organismal fitness.  By removing the fitness 
constraint, enzymes can be evolved for a new set of criteria including enhanced thermostability1-6, 
improved catalytic activity7-9, or new substrate recognition10-14.      
Sequence space is controlled by the amino acid context available for protein synthesis.  By 
performing codon reassignment to enable global replacement of a canonical amino acid with an 
artificial amino acid, sequence space is broadened beyond what was previously accessible by 
nature.  Cirino et al. demonstrated global replacement of methionine by norleucine enabled 
improved peroxygenase activity by cytochrome P450, but the tradeoff involved significantly 
reduced thermostability15.  Not all proteins are as permissive to global replacement; non-canonical 
amino acid incorporation can be similar to deleterious mutations depending on the deviation of the 
side chain from its natural counterpart.   
For over 50 years, researchers have been exploring the use of fluorinated amino acids in 
organisms16-21.  The Tirrell Lab has pioneered work in exploring proteins of fluorinated amino acid 
compositions through the use of residue specific incorporation22-24. Tang et al. has demonstrated that 
trifluorinated (Figure 3.1 [2]) and hexafluorinated (Figure 3.1 [3]) versions of leucine (Figure 3.1 
[1]) provide substantial improvements to protein stability in leucine zippers25,26.  However, 
attempting to enhance the stability of enzymes using trifluoroleucine is not so straightforward. 
Global incorporation of trifluoroleucine into complex, folded proteins results in decreased 
functionality.  Rather than throw away millions of years of evolution and attempt to build proteins 
from the ground up, directed evolution was applied to recover the lost properties.  Yoo et al. 
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demonstrated that green fluorescent protein (GFP) required eleven rounds of directed evolution to 
create a trifluoroleucine GFP variant with similar spectral properties to leucine version of GFP27.  
Montclare et al. has demonstrated that incorporation of trifluoroleucine into chloramphenicol 
acetyltransferase (CAT) results in 20 fold loss in protein half-life at 60oC.  Two rounds of directed 
evolution resulted in a trifluoroleucine CAT variant with half-life at 60oC comparable to that of 
wild-type CAT expressed with leucine.  In either case, directed evolution did not yield a protein that 
had improved properties when expressed with trifluoroleucine compared to leucine.  
In evolving trifluoroleucine versions of GFP and CAT, protein engineers were limited by the 
endogenous activity of leucyl-tRNA synthetase (LeuRS) toward trifluoroleucine.  Incorporation 
levels of trifluoroleucine into either protein never exceeded 80%, allowing for two to four leucine 
codons to be decoded as leucine instead of trifluoroleucine.  Residue-specific incorporation is 
incapable of controlling which leucine codons are decoded as trifluoroleucine or leucine; proteins 
evolved for trifluoroleucine are in fact evolved for tolerance to leucine or trifluoroleucine.  The goal 
of creating proteins that prefer trifluoroleucine over leucine is not possible without quantitative 
replacement; another amino acid was required to explore proteins of completely novel composition. 
Homoisoleucine (Figure 3.1 [4]) is a structural analogue of trifluoroleucine where the trifluoro 
group is replaced by a methyl group; replacement of leucine by homoisoleucine approaches 100% 
when proteins are expressed in leucine auxotrophs with overexpressed wild-type LeuRS.  Van 
Deventer et al. demonstrated that homoisoleucine incorporation into the leucine zipper A1 increased 
the melting temperature by17oC28, exceeding the stabilizing effect of (2S,4R)-trifluoroleucine 
isomer29.  Here we describe our attempts to evolve CAT expressed in homoisoleucine.  
Additionally, we look at a CAT mutant previously evolved for trifluoroleucine to determine how 
homoisoleucine and trifluoroleucine incorporation affect thermostability.   
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Results and Discussion 
Sequence diversity in CAT was introduced using error-prone PCR. Starting with an initial library 
size on the order of 107, we attempted to screen CAT variants using a previously described 96 well 
plate assay30.  Using a criterion of increased activity compared to wild type CAT after 1 hr. long 
incubation at 60oC, 1056 variants from the CAT library were screened.  The top six variants from 
each plate were used to inoculate a plate for comparison.  CAT variants with the highest activity 
after 60oC incubation were sequenced; only two out of twelve variants exhibited amino acid 
substitutions.  The two variants were expressed and purified in batch conditions; neither variant 
exhibited any improvement in thermostability compared to wild type CAT. 
A selection was performed to attempt to cull non-functioning variants as well as wild type CAT 
from the library.  The original CAT library was grown in M9 containing all 20 amino acids; 
expression of the CAT variants was induced after shifting to M9 media containing 19 amino acids 
plus homoisoleucine.  After a 15 min. expression period, aliquots were removed from the culture 
and spread on LB agar plates containing chloramphenicol (175 µg/L).  Sequencing of 24 colonies 
after one round of selection resulted in no truncated variants; however, 75% of sequenced variants 
were still wild-type.  An additional round of selection performed at higher concentrations of 
chloramphenicol (425 µg/L and 850 µg/L) did not yield any changes in the distribution of wild type 
CAT to CAT variants in the library population.  Variants from the library after one round of 
selection were screened for activity after one hour incubation at 65oC.  Of the 88 variants screened, 
eight of the ten highest activity variants did not contain any amino acid changes from wild-type. 
Lacking success in screening CAT variants expressed in homoisoleucine for improved 
thermostability, we looked at the effects of homoisoleucine incorporation on a previously evolved 
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CAT variant30.  Obtained through screening CAT libraries expressed in trifluoroleucine, L2A1 
could potentially have acquired mutations that confer stability against homoisoleucine 
incorporation.  Expression of wild-type CAT or L2A1 was carried out in M9 minimal media 
containing all 20 amino acids, 19 amino acids plus trifluoroleucine, or 19 amino acids plus 
homoisoleucine (Figure 3.2).  As expected, expression in leucine gave the greatest yields of wild-
type CAT or L2A1 (59.1 and 44.2 mg/L respectively) while trifluoroleucine expression produced 
the least wild-type CAT or L2A1 (3.15 and 3.43 mg/L respectively).  Yields of wild-type CAT and 
L2A1 expressed in homoisoleucine (5.82 and 6.89 mg/L respectively) were approximately twice 
those of trifluoroleucine.  Incorporation levels of trifluoroleucine (80%) and homoisoleucine 
(>95%) were consistent with previous work (Figure 3.3)26,28,30. 
L2A1 variants expressed in leucine, trifluoroleucine, and homoisoleucine were subjected to 
incubation at elevated temperatures to examine amino acid effects on thermostability (Figure 3.4).  
Consistent with previous work, the leucine form of L2A1 (Tm = 66.8oC) is more stable than the 
trifluoroleucine form (Tm = 61.7oC).  Quantitative incorporation of homoisoleucine into CAT (Tm 
= 54.5oC) results in a significant loss of thermostability compared to both leucine and 
trifluoroleucine.  The mutations that stabilize L2A1 for trifluoroleucine do not appear to confer any 
stabilization with respect to homoisoleucine incorporation; L2A1 and wild-type CAT (Tm = 
54.3oC) expressed with homoisoleucine show similar behavior when exposed to elevated 
temperatures (Figure 3.5).   
Similar trends are observed when looking at the half-life of L2A1 at 60oC.  L2A1 expressed in 
leucine (t1/2 = 42.9 min) exhibited 5.7 fold greater half-life than L2A1 expressed in trifluoroleucine 
(t1/2 = 7.5 min., Figure 3.7).  The leucine and trifluoroleucine forms of L2A1 exhibit shorter half-life 
at 60oC compared to previous work30; a 1.3 fold reduction of half-life between trifluoroleucine and 
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leucine forms was previously observed by Montclare et al.  Negligible differences were observed 
between either wild-type CAT (t1/2 = 1.2 min) or L2A1 (t1/2 = 1.5 min) expressed in homoisoleucine 
(Figure 3.8).   
   
Future Directions      
Limitations in protein expression with homoisoleucine could be interfering with the screening 
process.   Experiments with the purified, homoisoleucine form of wild-type CAT show that the 
protein half-life at 60oC is in the order of 90 sec..  The enrichment of wild-type CAT in the 
screening process suggests that expression of the protein may be occurring under conditions where 
leucine is present.  False positives could arise from leaky expression of the enzyme while in 
leucine-containing media or from incomplete leucine depletion before IPTG induction.  We are 
exploring other expression vectors (such as those with arabinose inducible promoters to limit 
undesired protein expression), and optimization of the conditions used for leucine depletion.  
Attempts to evolve a CAT variant that could tolerate quantitative incorporation of homoisoleucine 
may be limited by a marginally stable starting enzyme.  It has been shown that thermostable 
enzymes are more accommodating to neutral/deleterious mutations that would benefit desired 
enzyme properties31-33.  Utilizing a CAT enzyme derived from a thermophilic organism or evolving 
a leucine version of CAT for enhanced thermostability may create a better framework to study 
homoisoleucine.  It may also be beneficial to introduce a preliminary step into the evolution 
process, in which CAT would be expressed with both homoisoleucine and leucine in the media.  
This would allow the accumulation of stabilizing mutations and remove leucine positions where 
homoisoleucine replacement is not tolerated.  Later, as the protein become more stable, leucine 
would be removed and evolution would continue in a completely homoisoleucine context.  This 
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technique has been previously employed for GFP where 80% trifluoroleucine incorporation reduced 
GFP fluorescence to background levels due to protein misfolding/aggregation27.          
Homoisoleucine incorporation provides increased thermostability to coiled-coiled proteins, but this 
did not translate to globular proteins.  Quantitative replacement of leucine by homoisoleucine 
creates an enzyme of completely novel composition, but results in significant reduction of L2A1’s 
thermostability compared to proteins expressed in leucine- or trifluoroleucine-containing media.  
Although evolved to recover lost thermostability upon incorporation of trifluoroleucine, L2A1 does 
not show any additional stability over wild-type CAT after homoisoleucine incorporation.  Kwon et 
al. showed that hydration dynamics around homoisoleucine and trifluoroleucine residues differed34; 
mutations that stabilize for trifluoroleucine may not necessarily work for homoisoleucine.  We 
continue to build upon this work and move toward developing proteins that have a preference for an 
unnatural sequence space, potentially accessing new properties not possible in nature’s sequence 
space.   
 
Materials and Methods 
Cloning of CAT expression vector 
All restriction enzymes and ligases used in this work were supplied by NEB.  High fidelity 
polymerase PfuUltraII and error prone polymerase Mutazyme II are supplied by Agilent 
Technologies.  In order to ensure high levels of replacement of leucine with homoisoleucine, a 
constitutively expressed copy of the LeuRS was cloned into the expression vector pQE-80L.  
LeuRS was cloned from E. coli genomic DNA and ligated into the NheI restriction sites of pQE-
80L, creating the plasmid pQE-80L/LeuRS.  The plasmid pCCCAT, constructed as described by 
Montclare30, was digested with BamHI and HindIII to generate the gene for CAT; pQE-80L/LeuRS 
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was likewise digested with BamHI and HindIII to prepare the vector for ligation.  The CAT gene 
was ligated into the multi-cloning site of pQE-80L/LeuRS with T4 DNA ligase, creating the 
plasmid pQE-80L/LeuRS/wtCAT.  The same procedure was employed to generate the plasmid 
pQE-80L/LeuRS/L2A1; L2A1 is an evolved version of CAT stabilized for trifluoroleucine 
incorporation30.   
 
Construction of CAT gene library 
Mutazyme II was employed for error prone amplification of the CAT gene.  The library was 
prepared using pCCCAT and primers upstream of BamHI (5’-GTGAGCGGATAACAATTTCAC 
ACAG-3’) and HindIII (5’-CAACCGAGCGTTCTGAACAAATC-3’) restriction sites.  The 
randomized CAT gene was excised with BamHI and HindIII and then ligated into pQE-80/LeuRS.  
The library was transformed into DH10B containing pREP4, yielding a library of 1.5x107 based on 
the total number of transformants.  Sequencing revealed a mutation rate of three to four base pair 
substitutions per CAT gene. 
 
Thermostability screening in 96 well plates 
CAT variants from the library were inoculated into 96 well plates containing 250 µL LB media.  
The first column for each 96 well plate was reserved for wild-type CAT.  Cultures were grown 
overnight at 30oC, 70% humidity with 200 RPM shaking.  Overnight 96 well cultures were used to 
inoculate a new 96 well plate containing 250 µL of M9 minimal media (M9 salts, 0.2% glucose, 1 
mM MgSO4, 0.1 mM CaCl2, 35 mg/L Vitamin B) supplemented with all 20 canonical amino acids 
(each at 40 mg/L), ampicillin (200 µg/L), and kanamycin (35 µg/L).  After 12 hr. of growth (30oC, 
70% humidity with 200 RPM shaking), 96 well plates were centrifuged at 4000 RPM (6 min., 4oC) 
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and the medium was decanted.  Cold, isotonic NaCl was added to each well and pellets were 
resuspended using a Beckman Multimek 96-channel pipetting robot.  After repeating the wash step 
once, cells were resuspended in fresh M9 minimal media containing 19 amino acids minus leucine 
plus 500 µM homoisoleucine and 2 mM IPTG.  Expression was carried out for 6 hours after which 
cells were pelleted at 4000 RPM for 6 min. at 4oC.  Plates were stored at -80oC until assayed. 
 
Cell pellets in 96-well plates were thawed at room temperature and resuspended into 200 µL 50 
mM Tris pH 7.8, 0.5 mg/mL lysozyme, 0.5 units/ml of DNAseI, 0.25X B-PERII.  Plates were 
incubated at 37oC for 30 min. and then lysates were clarified by centrifugation at 4000 RPM for 6 
min. at 4oC.  Plates were heated to 60oC in a water bath for 1 hr. and cooled back to room 
temperature in an ice bath.  Lysates were clarified again before assays were performed.  An aliquot 
of lysate (10 µL) was transferred to a 96 microwell plate containing 35 µL 50 mM Tris pH 7.8.  The 
2x reaction buffer (50 µL) comprised of 50 mM Tris pH 7.8, 2 mM 5’,5’-dithiobis-(2-nitrobenzoic 
acid) (DTNB, Sigma), 0.8 mM acetyl-Coenzyme A, and 0.50 mg/mL BSA was added.  The 
reaction was started by addition of 5 µL of chloramphenicol (final concentration 100 µM).  
Acetylation of chloramphenicol generates Coenzyme A; the free thiol of Coenzyme A reacts with 
DTNB creating 2-nitro-5-thiobenzoate, a yellow product.  Formation of 2-nitro-5-thiobenzoate is 
monitored by measuring absorbance at 412 nm with a Tecan Safire2 96 well microplate reader.    
Variants displaying the highest activity after incubation at 60oC were pooled from all assayed plates 
and tested again for activity at room temperature prior to heating and after heating to 60oC. 
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Selection of CAT library for variants active after homoisoleucine incorporation 
Cultures of E. coli strain DH10B containing pREP4 and pQE-80L/LeuRS/CAT library were grown 
at 37oC to mid-log phase (OD600 ~ 0.8-1.0) in M9 minimal media (M9 salts, 0.2% glucose, 1 mM 
MgSO4, 0.1 mM CaCl2, 35 mg/L Vitamin B) supplemented with all 20 canonical amino acids (each 
at 40 mg/L), ampicillin (200 µg/L), and kanamycin (35 µg/L).  Upon reaching mid-log phase, cells 
were pelleted and washed thrice using 0.9% NaCl to deplete leucine.  Cells were subsequently 
resuspended in M9 minimal media supplemented with 19 amino acids minus leucine plus 500 mM 
homoisoleucine.  Addition of 1 mM IPTG to the media initiated expression of the CAT library.  
After 15 min., aliquots were removed from the culture and plated directly onto LB plates containing 
200 µg/L ampicillin, 35 µg/L kanamycin, and 170 µg/L chloramphenicol.  Colonies from plating 
were used directly to create new library stocks.     
 
Batch expression of CAT variants 
Expression of 6xHis-tagged CAT or 6xHis-tagged L2A1 was carried out in leucine auxotrophic 
DH10B/pREP4 bearing the plasmid pQE-80L/LeuRS/CAT or pQE-80L/LeuRS/L2A1.  Cultures of 
DH10B/pREP4 containing pQE-80L/LeuRS/CAT or pQE-80L/LeuRS/L2A1 were grown at 37oC 
to mid-log phase (OD600 ~ 0.8-1.0) in M9 minimal media (M9 salts, 0.2% glucose, 1 mM MgSO4, 
0.1 mM CaCl2, 35 mg/L Vitamin B) supplemented with all 20 canonical amino acids (each at 40 
mg/L), ampicillin (200 µg/L), and kanamycin (35 µg/L).  Upon reaching mid-log phase, cells were 
pelleted and washed thrice using 0.9% NaCl to deplete leucine.  Cells were subsequently 
resuspended in M9 minimal media supplemented with all 20 amino acids, 19 amino acids minus 
leucine and plus 1mM trifluoroleucine, or 19 amino acids minus leucine plus 500 µM 
homoisoleucine.  6xHis-tagged, CAT or L2A1 expression was induced by the addition of 1 mM 
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IPTG and carried out for 12 hr. Cells were pelleted at 8000g at 4oC for 10 min. and frozen at -80C.   
Cell pellets were lysed using 0.5 mg/ml lysozyme (Sigma) in 50 mM Tris pH 7.8 supplemented 
with 10% glycerol, 0.5 units of DNAseI, and 0.25X B-PERII (Pierce).  Cells were treated for a total 
of 30 sec. sonication using 5 sec. on pulses followed by 10 sec. rest.  Lysates were clarified by 
centrifugation at 10,000g at 4oC for 30 min..  Ni-NTA resin (Qiagen) was added to the clarified 
lysate and allowed to bind for 2 hr. at 4oC.  After binding, the resin was loaded into a 
chromatography column and washed twice using 50 mM Tris pH 7.8, 10% glycerol, 25 mM 
imidazole.  CAT or L2A1, bearing a N-terminal 6xHis-tag, was eluted using 50mM Tris pH7.8, 
10% glycerol, 250 mM imidazole.  Samples from all steps were analyzed by SDS-PAGE to confirm 
purity and eluted protein concentrations were verified using BCA assay. 
 
Measuring residual activity of CAT variants after incubation at elevated temperatures 
Purified 6xHis-tagged CAT or L2A1 samples containing leucine, trifluoroleucine, or 
homoisoleucine were incubated with 0.25 mg/ml bovine serum albumin at various temperatures 
using a thermocycler ranging from 30oC to 75oC for 30 min. followed by 5 min. incubation at 30oC.  
A 2x reaction buffer comprised of 50 mM Tris pH 7.8, 2 mM DTNB, 0.8 mM acetyl-Coenzyme A 
was added to aliquots of CAT or L2A1.  The activity was assayed at 25oC after the addition of 100 
µM chloramphenicol.   
 
Half-life determination of CAT variants at 60oC 
Purified 6xHis-tagged CAT or L2A1 containing leucine, trifluoroleucine, or homoisoleucine were 
incubated with 0.25 mg/ml bovine serum albumin at 60oC for various times ranging from 0 to 120 
min. using a thermocycler followed by a 10 min. incubation at 25oC.  A 2x reaction buffer 
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comprised of 50 mM Tris pH 7.8, 2 mM DTNB, 0.8 mM acetyl-Coenzyme A was added to aliquots 
of CAT or L2A1.  The activity was assayed at 25oC after the addition of 100 µM chloramphenicol. 
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Figure 3.1 
 
Structures of amino acids discussed in this chapter: 1: Leucine; 2: Trifluoroleucine; 3: 
Hexafluoroleucine; 4: Homoisoleucine   
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Figure 3.2 
 
Native purification of his-tagged wild-type CAT and L2A1 expressed in media containing 
leucine, trifluoroleucine, or homoisoleucine.  Wild-type CAT and an evolved version of CAT, 
L2A1, were expressed in leucine auxotrophic DH10B with overexpression of the wild-type LeuRS.  
Protein bands corresponding to 6xHis-CAT (expected mass: 27.417 kDa) or 6xHis-L2A1 (expected 
mass: 27.429 kDa) are observed in lysate lanes at the correct molecular weights.  Protein is 
successfully loaded onto the column (absence of CAT band in lane FT) and minimal protein loss is 
observed with imidazole washes (lane W2).  Protein eluted from the column is concentrated from 
the original sample and good yields are obtained for CAT or L2A1 expressed in leucine rich media.  
Approximately eight-fold reduction in protein yield is observed for expression carried out in 
homoisoleucine compared to leucine.  Homoisoleucine media supports two-fold greater protein 
yields compared to trifluoroleucine media.  
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Figure 3.3 
 
L2A1 expression with leucine, trifluoroleucine, and homoisoleucine demonstrates limits of 
replacement.  Expression of L2A1 is carried out in a leucine auxotrophic strain with constitutively 
expressed wild-type LeuRS.  Purified L2A1 was subjected to trypsin digestion and peptides were 
analyzed on MALDI-TOF MS.  The peptide LMNAHPEFR was found at the expected mass when 
all 20 amino acids were added to the expression media (top panel).  Trifluoroleucine is found to 
replace leucine at approximately 80%, which is consistent with previous work30 (middle panel).  
Quantitative replacement of leucine by homoisoleucine is observed; complete shift of the peptide 
mass peak by a 14 Da increase (bottom panel).   
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Figure 3.4 
 
Thermostability of L2A1 is reduced by incorporation of trifluoroleucine and homoisoleucine.  
Purified L2A1 expressed with leucine, trifluoroleucine, or homoisoleucine was assayed for activity 
after 30 min. incubation at elevated temperatures (top panel).  The leucine version of L2A1 exhibits 
the greatest thermostability followed by the trifluoroleucine version (top panel); L2A1 was evolved 
for increased thermostability with leucine positions decoded as trifluoroleucine.  Mutations that 
stabilize L2A1 for trifluoroleucine do not provide any significant benefit when homoisoleucine is 
quantitatively incorporated (bottom panel).   
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Figure 3.5 
 
Rapid inactivation of the homoisoleucine form of L2A1 is observed upon exposure to elevated 
temperatures.  Purified L2A1 expressed with leucine, trifluoroleucine, or homoisoleucine was 
incubated at 60oC; aliquots were removed over a period of two hours and assayed for activity. The 
leucine form of L2A1 exhibits approximately 6-fold and 30-fold greater half-life at 60oC than 
trifluoroleucine and homoisoleucine versions of L2A1 respectively (top panel).  Wild type CAT and 
L2A1 exhibit similar inactivation rates when homoisoleucine is quantitatively incorporated (bottom 
panel).    
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CHAPTER 4 
 
Introduction of New Chemical Functionality into Engineered 
Proteins through Incorporation of Novel Non-Canonical Amino 
Acids 
 
 
 
 
 
 
 
 
 
 
Azidomethylphenylalanine and aminomethylphenylalanine work was done in collaboration 
with Professor Adam Urbach and Leigh Anna Logsdon from Trinity University (San 
Antonio, TX). 
    
Furanylalanine work was done in collaboration with Dr. Janek Szychowski.  
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Abstract 
There still exists a great disparity between the chemical reactions available to synthetic 
chemists and those accessible to protein chemists.  Recently, cross metathesis and Diels-
Alder chemistry were made accessible through site-specific incorporation of artificial 
amino acid analogues bearing crotyl oxides and norbornene functional groups.  Here we 
demonstrate the incorporation of three new artificial amino acids that provide access to new 
chemistries not previously explored via residue-specific replacement.  S-allyl-
homocysteine, a methionine analogue, and furanylalanine, a phenylalanine analogue, can 
be incorporated into auxotrophic strains without any genetic modification of the host 
organism.  Azidomethylphenylalanine requires the expression of a mutant phenylalanine 
synthetase for metabolic labeling of proteins. 
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Introduction 
Artificial protein sequence space contains a broad range of functional groups, many of 
which add to the repertoire of chemistries available for protein modification.  In order to 
expand sequence space to include novel chemistries, we describe the use of synthetic 
chemistry to create three new non-canonical amino acids for residue-specific incorporation: 
S-allyl-homocysteine, furanylalanine, and azidomethylphenylalanine.  This chapter 
describes their potential applications and the work required to utilize these new amino acids 
for metabolic labeling of proteins.     
S-allyl-homocysteine 
Olefin metathesis has provided chemists the ability to form new carbon-carbon bonds, 
enabling synthesis of polymers with low polydispersity from a wide range of monomers 
containing linear and cyclic alkenes1-4.  Solid-phase synthesis has enabled chemists to 
incorporate alkene side chains into peptides; peptides stapled using cross metathesis have 
been designed to act as inhibitors of transcription factor assembly in vivo5.  The typical 
solvents (nonpolar alkanes, benzene, etc) and reaction conditions used to perform cross 
metathesis are not favorable for protein solubility or stability; metathesis has long been 
considered undesirable as a means of functionalizing whole proteins.  Recently, the Davis 
lab has demonstrated that aqueous cross metathesis is possible given the proper protein side 
chain6.  Allyl sulfides were shown to be the ideal choice for cross metathesis using 
ruthenium-based Grubbs catalysts. 
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Although allylic amino acid analogues have been incorporated in a residue specific manner 
into proteins7, allyl sulfides have only been incorporated through amino acid modifications 
and site specific incorporation.  Chemical modification of cysteine on the protein surface 
enables a route to install S-allyl-cysteine (Figure 4.1 [2]); however, careful choice of 
protein or engineering of proteins are necessary to prevent multiple modifications or 
disruption of disulfide bonds8.  The Schultz lab has demonstrated incorporation via amber 
suppression of O-crotylserine (Figure 4.1 [3]) with oxygen at the allylic position; LC-ESI-
MS was used to detect the cross metathesis product between two spatially adjacent O-
crotylserine residues in circularly permutated Venus protein9.  Attempts to use S-allyl-
cysteine as a methionine-specific analogue in methionine-auxotrophic E. coli produced low 
but detectable incorporation6.   
In order to utilize cross metathesis for BONCAT, we explored other allyl sulfides that 
could be incorporated in a residue specific manner.  The inherent lack of carbon-carbon 
double bonds in proteins could enable selective modification using metathesis if a suitable 
alkene could be incorporated into proteins.  We surmised that an allyl sulfide with similar 
heteroatom position to methionine (Figure 4.1 [1]) could be incorporated by the methionyl-
tRNA synthetase (MetRS) or one of the known MetRS mutants.  We demonstrate here the 
synthesis of S-allyl-homocysteine (Figure 4.1 [4]), and we show that S-allyl-homocysteine 
can be used as a methionine analogue for global incorporation into proteins at near 
quantitative levels. 
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Azidomethylphenylalanine 
BONCAT has provided researchers with the ability to selectively enrich newly synthesized 
proteins from complex mixtures for analysis via mass spectroscopy10.  Through the 
incorporation of methionine analogues bearing azide or alkyne groups, proteins can be 
modified with [3+2] azide-alkyne click chemistry, enabling the attachment of affinity 
probes for enrichment.  Azidonorleucine and the mutant methionyl-tRNA synthetase NLL-
MetRS have further refined BONCAT to confine labeling to a subset of organisms, 
enabling identification of proteins in complex cellular mixtures11,12.    
Affinity purification in BONCAT is currently mediated through biotin-streptavidin 
interactions; attempts to remove newly synthesized proteins during enrichment have 
resulted in sample contamination, with streptavidin loss from its resin support due to the 
harsh conditions required to separate biotin from streptavidin.  Attempts to mitigate 
contamination have come through the development of affinity tags containing cleavable 
moieties that should not damage the resin-supported streptavidin13.  We sought to explore 
non-protein based affinity methods that could eliminate complications arising from excess 
streptavidin in samples prepared for mass spectrometry. 
Supramolecular chemistry provides many examples of host-guest interactions that could 
prove to be useful replacements for the biotin-streptavidin system.  We turned to a class of 
water-soluble macrocycles known as cucurbiturils: annular molecules formed by glycoluril 
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monomers linked by methylene units.  In particular cucurbit[7]uril (Q7, Figure 4.2), 
composed of 7 glycoluril monomers, has been demonstrated to bind a wide variety of 
targets including organic dyes, organometallics, drugs, and proteins14.  Phenylalanine 
(Figure 4.1 [5]) has previously been shown to bind with micromolar affinity to Q7; its 
aromatic ring fits into the non-polar cavity of Q7 while the amino acid backbone forms 
favorable electrostatic interactions with the carbonyl groups decorating the circular face of 
Q715.  The Urbach group has demonstrated that non-canonical phenylalanine analogs can 
bind with even greater affinity to Q7; furthermore, Q7 can recognize peptides with N-
terminal phenylalanine or phenylalanine analogs14.  Peptides that bear p-
aminomethylphenylalanine (Figure 4.1 [8]) at the N-terminus bind Q7 with KD of 9.5x10-10 
M16.  
The Tirrell lab has demonstrated the incorporation of a wide variety of phenylalanine 
analogues through the use of mutant phenylalanine-tRNA synthetases (PheRS).  Positions 
A294 and T251 in the binding pocket of E. coli PheRS can be mutated to glycine to enable 
the incorporation of a wide variety of bulkier phenylalanine analogues17.  Here we describe 
the synthesis and incorporation of p-azidomethylphenylalanine (Figure 4.1 [7]), a chemical 
precursor to p-aminomethylphenylalanine, into proteins.    
 
Furanylalanine 
The Diels-Alder reaction utilizes an electron-rich diene and electron-poor alkene, both of 
which are absent in the canonical protein side chains, to form new carbon-carbon bonds 
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through a [4+2] cycloaddition.  Through the modification of cysteine or lysine, chemists 
have installed a variety of dienes and dieneophiles onto proteins for subsequent 
modification through Diels-Alder reactions18.  The Ting group has recently demonstrated 
the incorporation of trans-cyclooctene functionality onto proteins mediated by an 
engineered lipoic acid ligase; an inverse-electron-demand Diels-Alder cycloaddition with a 
tetrazine probe that enables the attachment of fluorophores to specific proteins19.  Recent 
work by the Chin Lab and others has demonstrated the installation of cyclic alkene amino 
acids like Nε-5-norbornene-2-yloxy-carbonyl-L-lysine, through amber suppression, for 
inverse electron-demand Diels–Alder cycloaddition20,21.  
To incorporate a Diels-Alder reactive amino acid in a residue specific manner, we 
investigated an amino acid containing the furan functional group.  Among the earliest 
studied compounds for the Diels-Alder reaction22, furans have a large assortment of 
possible Diels-Alder partners including maleimides, activated alkenes, and alkynes23.  
Although furans are considered less reactive than other dienes because of their aromaticity, 
performing the reaction in aqueous conditions should help to improve reaction kinetics24,25. 
The furan-maleimide reaction has been utilized extensively for polymer synthesis26-29, 
taking advantage of the reversible nature of the Diels-Alder reaction30-32.   Here we 
describe the incorporation of furanylalanine into proteins as a phenylalanine analogue.  
Proteins metabolically labeled with furanylalanine can be modified through the attachment 
of maleimide probes.   
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Results and Discussion 
S-allyl-homocysteine   
MetRS has been known to activate a variety of methionine analogues, including those that 
share methionine’s sulfur position33.  Homocysteine, a precursor to methionine, can be 
activated by MetRS; however, before homocysteine is transferred to tRNAMET, it is rapidly 
cyclized to homocysteine thiolactone34.  Ethionine, a methionine analogue with an ethyl 
group in lieu of the canonical methyl group, is also activated by the MetRS but is 
deacylated from tRNAMET 35.  We synthesized S-allyl-homocysteine (Figure 4.3), an allyl 
sulfide containing methionine analogue that shares the canonical position of sulfur, for test 
expressions in methionine auxotrophs. 
Expression of GFPrmAM in media containing 19 amino acids without methionine is made 
possible by supplementation of the media with 1mM S-allyl-homocysteine.  Replacement 
of methionine by S-allyl-homocysteine was determined from purified GFPrmAM to be 
approximately 40% by MALDI-TOF MS (Figure 4.4).  Previous work by Kiick et al. had 
demonstrated that poorly activated methionine analogues could be incorporated with 
overexpression of the wild-type MetRS36.  By including a constitutively expressed copy of 
the MetRS in the GFPrmAM expression plasmid, near complete replacement of methionine 
by S-allyl-homocysteine was observed (Figure 4.4).  
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Azidomethylphenylalanine 
The side chain amine group of p-aminomethylphenylalanine, a high affinity guest for Q7, is 
protonated under physiological conditions, making it an unlikely substrate for activation by 
PheRS.  The Staudinger reduction enables the conversion of azides to amines through 
treatment with phosphine37; p-azidomethylphenylalanine could be incorporated in the place 
of p-aminomethylphenylalanine and subsequently reduced to yield the desired amino acid.  
Precedent for incorporating azides at the para position of phenylalanine exists; p-
azidophenylalanine (Figure 4.1 [6]) has been incorporated into proteins by the mutant 
PheRS-A294G to crosslink artificial protein biomaterials 17,38.  p-Azidomethylphenyalanine 
was synthesized via diazotransfer from commercially available p-
aminomethylphenylalanine to test for activation by PheRS mutants. 
Incorporation of azide analogues into proteins can be detected by treatment of cellular 
lysates with fluorescent alkyne probes (Figure 4.5).  Overexpression of wild-type PheRS or 
any of the PheRS mutants in the canonical 20 amino acids does not permit the attachment 
of dibenyzlcyclooctyne conjugated carboxytetramethylrhodamine (DIBO-TAMRA, 11) to 
cellular proteins.  Metabolic labeling of proteins with p-azidophenylalanine or p-
azidomethylphenylalanine is not observed in cases where the wild-type PheRS is 
overexpressed.  Lysates from cultures with overexpressed PheRS mutants display DIBO-
TAMRA modified proteins if p-azidomethylphenylalanine is added post-media shift.  
Similarly, if p-azidophenylalanine, a known analogue for PheRS-A294G, PheRS-T251G, 
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and PheRS-A294G&T251G, is added post media shift, lysates from cultures with 
overexpressed PheRS mutants are modified by DIBO-TAMRA. 
Furanylalanine 
3-Thienylalanine (9), a thiophene analogue of phenylalanine, has been previously 
incorporated into proteins by Kothakota et al39.  We rationalized that since 3-furanylalanine 
(10) and 3-thienylalanine are structurally very similar, furanylalanine would be amenable 
for residue specific replacement of phenylalanine.  Furthermore, if furanylalanine could not 
be incorporated by the wild-type PheRS, many well characterized mutant PheRSs (PheRS-
A294G, PheRS-T251G, PheRS-A294G&T251G) could serve as means to incorporate 
furanylalanine, albeit in a cell-specific manner.   
Incorporation of furanylalanine was confirmed through the overexpression of wild-type 
PheRS under the control of an IPTG-inducible promoter in a phenylalanine auxotrophic 
strain (Figure 4.6).  Levels of furanylalanine incorporation in PheRS are difficult to 
quantify since the probability of replacement is dependent on the quantity of induced wild-
type PheRS expression.  Assuming wild-type PheRS is not rendered inactive by 
furanylalanine incorporation, PheRS synthesized at the end of the expression window 
should have higher incorporation levels than PheRS produced shortly after induction.  
However, it is worthwhile to note that trypsin digested peptides from wild-type PheRS are 
observed to have multiple phenylalanine positions replaced with furanylalanine via 
MALDI-TOF MS.  Expression of green fluorescent protein in non-phenylalanine 
auxotrophic strains without the overexpression of the wild-type PheRS yielded 
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furanylalanine replacement of approximately 10 percent (Figure 4.7).  Metabolic labeling 
of proteins with furanylalanine can occur with simple media shift, making it a potential 
amino acid analogue for BONCAT if a bio-orthogonal Diels-Alder reaction could be 
found. 
The Diels-Alder reaction between maleimides and furans yields [4π+2π] cycloaddition 
products at room temperature, making it an attractive means of attaching molecules to 
proteins labeled with furanylalanine18.  However, maleimides cannot be considered bio-
orthogonal due to the competing Michael addition with cysteines, and to a lesser extent, 
amines.  Attachment of a biotinylated maleimide tag (12) to purified wild-type PheRS was 
carried out following a reduction and iodoacetamide alkylation step (Figure 4.8).  The 
alpha subunit of wild-type PheRS labeled with furanylalanine is observed to have a 
distribution of increased molecular weights, due to the attachment of 12 at multiple 
furanylalanine positions.  Visualizing biotinylated proteins with streptavidin demonstrates 
the lack of bio-orthogonality of the maleimide-furan reaction; wild-type PheRS expressed 
without furanylalanine is nonspecifically biotinylated, as seen in middle panel of Figure 
4.8.  The alpha subunit of PheRS has a single cysteine codon compared to 20 phenylalanine 
codons; the lack of bio-orthogonality could hamper the use of furanylalanine for BONCAT 
where cysteine content of proteins is unknown.   
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Future Directions 
Although S-allyl-homocysteine can be incorporated extensively at methionine positions, 
attempts to perform cross-metathesis to attach alkene probes on labeled proteins have thus 
far been unsuccessful.  A combination of factors could be hindering the intermolecular 
reaction.  Proteins and catalyst have different preferences for the liquid phases; catalysts 
that have increased water solubility would assist in improving metathesis for conjugation of 
probes to proteins.  Intramolecular reactions of multiple S-allyl-homocysteine residues on a 
single protein or intermolecular reactions of proteins would result in undesired side 
products.  Methionine replacement could be lowered using less S-allyl-homocysteine, thus 
helping to reduce intramolecular reactions.  However, controlling intermolecular reactions 
could be difficult if the intent is to use S-allyl-homocysteine for BONCAT, unless reactions 
were run in extremely dilute conditions.  There are conditions where intermolecular 
reactions between proteins could be favorable, such as the formation of protein gel 
networks.  Additionally, thiol-ene chemistry could utilize the allyl-sulfide side chain of S-
allyl-homocysteine. 
Ongoing work with aminomethylphenylalanine has provided additional motivation for 
improving the incorporation of azidomethylphenylalanine.  Recent developments in the 
Urbach group have shown Q7 is capable of interfering with exopeptidase activity (Figure 
4.9).40  Peptides with internal aminomethylphenylalanine residues can be treated with non-
specific aminopeptidase; when N-terminal aminomethylphenylalanine is generated, Q7 
binds and inhibits further exopeptidase activity.  By combining proteolysis and affinity 
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purification in one step without the need for streptavidin, this could provide a means to 
simplify enrichment of newly synthesized proteins labeled with 
aminomethylphenylalanine.  Q7 is currently being modified to enable attachment to a solid 
support, enabling flow purification in a column format.   
Connor et al. have demonstrated another way to generate proteins with N-terminal 
phenylalanine analogues41.  L,F-transferase performs the post-translational addition of 
leucine or phenylalanine to proteins bearing N-terminal basic residues; L,F-transferase 
plays a vital role in the protein degradation pathway known as the N-end rule42.  Connor et 
al. showed that L,F-transferase has flexible substrate specificity; for example, it is capable 
of utilizing azidophenylalanine-tRNAPhe aminoacylated by PheRS-A294G.  Extension of 
the L,F-transferase system would be straightforward with azidomethylphenylalanine, 
allowing for the generation of full length proteins as potential guests for the Q7.      
Saturation mutagenesis of other binding pocket positions of PheRS could be performed to 
create libraries for screening improved PheRS mutants for azidomethylphenylalanine 
incorporation.  Fluorescence activated cell sorting has already been demonstrated for 
screening libraries of aminoacyl-tRNA synthetases for improved activation of azide 
bearing amino acids43; a high throughput screening method could enable faster discovery of 
PheRS mutants specific for azidomethylphenylalanine. 
Further investigations of Diels-Alder reactions specific for furanylalanine are currently on-
going.  Furan-maleimide chemistry provides interesting applications for the formation of 
hydrogels with cysteine-free proteins, including those that could be thermally sensitive to 
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retro Diels-Alder.    However, the ideal reaction would be bio-orthogonal to enable greater 
flexibility for protein modification and use in the discovery of newly synthesized proteins. 
Here we have demonstrated three new artificial amino acids that can be used for metabolic 
labeling of proteins.  All three amino acids highlight new avenues for protein chemistry not 
afforded by the current crop of non-canonical amino acids used for residue specific 
incorporation.  Although binary interactions between organisms can be interrogated with 
propargylglycine and azidonorleucine, most multi-organism systems are far more complex.  
The further development of new bio-orthogonal chemistries which are orthogonal to each 
other could provide new methods of examining complex interspecies interactions.   
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Materials and Methods 
 
Synthesis of S-allyl-homocysteine 
N-Boc-DL-S-allyl-homocysteine methyl ester (Figure 4.3a, i) was synthesized according to 
previously reported synthesis from the Davis Lab6.  De-protection of i: 520 mg of i was 
dissolved in 10 mL of CH2Cl2.  1 mL of TFA was added and resulting mixture was stirred 
at room temperature for 4 hours.  Solvent was evaporated under reduced pressure and 
resulting yellow oil was dissolved in 10 mL of THF.  While this solution was stirred over 
an ice bath, 25 mL of 5 M LiOH was added.  The reaction was allowed to warm up to room 
temperature and stirred for 2 hr..  ddH2O (35mL) was then added to the reaction mixture 
followed by DOWEX® 50Wx8 (~50 g) and loaded into an empty column.  The resin was 
washed with 250 mL of H2O and product was eluted with 5% NH4OH.  Solvent was 
evaporated under reduced pressure resulting in a yellow solid which was further purified 
using silica gel chromatography (1-10% gradient of MeOH in CH2Cl2) producing S-allyl-
homocysteine (ii) (220.4 mg, 67%.) 1H NMR: (500 MHz, D2O) δ 5.83 – 5.73 (m, 1H), 
5.16 – 5.07 (m, 2H), 3.25 (dd, J = 7.3, 5.6 Hz, 1H), 3.17 – 3.13 (m, 2H), 2.51 – 2.46 (m, 
2H), 1.89 – 1.79 (m, 1H), 1.78 – 1.68 (m, 1H).  13C NMR: (126 MHz, D2O) δ 182.72, 
133.86, 117.47, 55.22, 34.26, 33.39, 26.16.  TOF MS ES+: Expected mass for C7H14NO2S 
is 176.0745; found 176.0709.   
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Determination of S-allyl-homocysteine incorporation 
Expression of his-tagged GFP_rmAM was carried out in methionine auxotrophic DH10B 
(TYJV2) strain using the plasmids pQE-80L/GFP_rmAM as well as pMTY13.  pMTY13 is 
pQE-80L/GFP_rmAM with a copy of the wild-type MetRS under control of its endogenous 
promoter44.  Cultures of TYJV2 containing pQE-80L/GFP_rmAM or pMTY13 were grown 
at 37oC to mid-log phase (OD600 ~ 0.8-1.0) in M9 minimal media (M9 salts, 0.2% glucose, 
1 mM MgSO4, 0.1 mM CaCl2, 35 mg/L Vitamin B) supplemented with all 20 canonical 
amino acids (each at 40 mg/L), and ampicillin (200 µg/L).  Upon reaching mid-log phase, 
cells were pelleted and washed twice using 0.9% NaCl to deplete methionine.  Cells were 
subsequently resuspended in M9 minimal media supplemented with 19 amino acids minus 
methionine plus 2 mM S-allyl-homocysteine.  GFP_rmAM expression was induced by the 
addition of 1 mM IPTG and carried out for 6 hr..  Cells were pelleted at 8000g and 4oC for 
10 min. and frozen at -80oC.  Cell pellet was lysed in 8 M urea with repeated freeze-thaw 
cycles and GFP_rmAM was purified under denaturing conditions using Ni-NTA agarose.  
Tryptic digests of purified GFP_rmAM were subjected to MALDI time-of-flight mass 
spectrometry with α-cyano-4-hydroxycinnamic acid as matrix.  An Applied Biosystems 
Voyager DE-PRO equipped with a 20-Hz nitrogen laser was used for all peptide analyses. 
 
Synthesis of L-azidomethylphenylalanine 
An ampule of triflic anhydride (10 g, 35.5 mmol) was added dropwise to a prechilled 100 
mL round bottomed flask containing sodium azide (10.6 g, 163 mmol) dissolved in 30 mL 
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deionized water submerged in an ice bath. The resulting mixture was stirred vigorously at 
room temperature for 90 min. and then extracted with three portions of dichloromethane 
(20 mL each). The organic layers were combined, washed twice with saturated sodium 
carbonate (30 mL each), and then added to a flask containing Boc-Phe(4-NH2CH2)-OH (1 
g, 3.4 mmol), potassium carbonate (0.7 g, 5.1 mmol), and cupric sulfate (0.084 g, 0.34 
mmol) in a mixture of 40 mL water and 80 mL methanol. The resulting light blue cloudy 
mixture was stirred overnight at room temp and then concentrated in vacuo to ~40 mL. The 
blue mixture was acidified with 6 M HCl to pH ~6, at which point blue clumps appeared. 
The clumps were removed by vacuum filtration, and the colorless filtrate was further 
acidified by addition of 6 N HCl. At pH 4 the mixture became cloudy, and at pH 2-3, the 
mixture was added to a separatory funnel and extracted with three portions of ethyl acetate 
(20 mL each). The organic layers were combined, dried over sodium sulfate, and 
concentrated in vacuo to a yellow oil with light yellow solid. This crude material was 
resuspended in concentrated HCl (4 mL) and mixed for 10 min. to yield a white precipitate. 
Water (25 mL) was added, and the yellow solution was concentrated to dryness by rotavap 
under high vacuum. The solid was resuspended in 20 mL water and lyophilized to dryness 
to yield a light tan, finely divided powder. Yield: 354 mg, 47%.  1H NMR: (400 MHz, 
DMSO-d6): 8.38 (br s, 3H), 7.33 (m, 4H), 4.42 (s, 2H), 4.18 (t, 1H, J = 7 Hz), 3.12 (d, J = 7 
Hz). 
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Testing azidomethylphenylalanine incorporation via overexpression of PheRS variants 
Expression of 6xHis-tagged, PheRS variants was carried out in KY14 using the plasmids 
pQE-80L/PheRS, pQE-80L/PheRS-A294G, pQE-80L/PheRS-T251G, and pQE-
80L/PheRS-A294G&T251G.  PheRS variants were cloned into the SphI and HindIII site in 
a similar manner to the way in which pQE-80L/PheRS was constructed, allowing for 
inducible expression of 6xHis-tagged PheRS variants upon the addition of IPTG.  Cultures 
of KY14 containing pQE-80L/PheRS, pQE-80L/PheRS-A294G, pQE-80L/PheRS-T251G, 
and pQE-80L/PheRS-A294G&T251G were grown at 37oC to mid-log phase (OD600 ~ 0.8-
1.0) in M9 minimal media (M9 salts, 0.2% glucose, 1 mM MgSO4, 0.1 mM CaCl2, 35 
mg/L Vitamin B) supplemented with all 20 canonical amino acids (each at 40 mg/L), and 
ampicillin (200 µg/L).  Upon reaching mid-log phase, cells were pelleted and washed twice 
using 0.9% NaCl to deplete phenylalanine.  Cells were subsequently resuspended in M9 
minimal media supplemented with all 20 amino acids, 19 amino acids minus phenylalanine 
and plus 1 mM L-azidophenylalanine, a known analogue activated by the listed PheRS 
variants, or 19 amino acids minus phenylalanine and plus 1 mM L-
azidomethylphenylalanine.  Expression of 6xHis-tagged PheRS variants was induced by 
the addition of 1 mM IPTG and carried out for 4 hours.  Cells were pelleted at 8000g and 
4oC for 10 minutes and frozen at -80oC.  The cell pellet was lysed in 8 M urea with 
repeated freeze-thaw cycles and 6xHis-tagged, wild-type PheRS was purified under 
denaturing conditions using Ni-NTA agarose.  Purified 6xHis-tagged PheRS variants 
expressed in 20 amino acids, L-azidophenylalanine, or L-azidomethylphenylalanine were 
subjected to strain-promoted, copper-free azide-alkyne click chemistry using 
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dibenzylcyclooctyne conjugated carboxytetramethylrhodamine (DIBO-TAMRA, 
Invitrogen).  Reaction was carried out in tris-buffered saline pH 7.4 with a 25 µM DIBO-
TAMRA for 30 minutes at room temperature in the dark.  Aliquots of the reaction mixture 
were mixed with SDS loading buffer and separated on 12% SDS-PAGE gel.  Proteins 
conjugated with DIBO-TAMRA were visualized using Typhoon Trio with 532 nm laser 
and 580 nm bandpass filter. 
Testing furanylalanine incorporation via overexpression of wild-type PheRS 
D,L-furanylalanine was synthesized according to a previously reported procedure45.  
Expression of the 6xHis-tagged, wild-type PheRS was carried out in methionine, 
phenylalanine, and lysine auxotrophic DH10B (KY14), prepared by Kai Yuet using lambda 
red recombination knockout, using the plasmid pQE-80L/PheRS.  The plasmid pQE-
80L/PheRS has the wild-type PheRS cloned into the SphI and HindIII sites, allowing for 
inducible expression of 6xHis-tagged wild-type PheRS upon addition of IPTG.  Cultures of 
KY14 containing pQE-80L/PheRS were grown at 37oC to mid-log phase (OD600 ~ 0.8-1.0) 
in M9 minimal media (M9 salts, 0.2% glucose, 1 mM MgSO4, 0.1 mM CaCl2, 35 mg/L 
Vitamin B) supplemented with all 20 canonical amino acids (each at 40 mg/L), and 
ampicillin (200 µg/L).  Upon reaching mid-log phase, cells were pelleted and washed twice 
using 0.9% NaCl to deplete phenylalanine.  Cells were subsequently resuspended in M9 
minimal media supplemented with 19 amino acids minus phenylalanine and plus 2 mM 
D,L-furanylalanine.  Expression of 6xHis-tagged, wild-type PheRS was induced by 
addition of 1 mM IPTG and carried out for 4 hr..  Cells were pelleted at 8000g and 4oC for 
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10 minutes and frozen at -80C.  The cell pellet was lysed in 8 M urea with repeated freeze-
thaw cycles and 6xHis-tagged, wild-type PheRS was purified under denaturing conditions 
using Ni-NTA agarose.  Trypsin digests of purified 6xHis-tagged, wild-type PheRS were 
subjected to MALDI-TOF MS with α-cyano-4-hydroxycinnamic acid as matrix.  An 
Applied Biosystems Voyager DE-PRO equipped with a 20-Hz nitrogen laser was used for 
all peptide analyses. 
 
Determination of L-furanylalanine incorporation via expression of GFPm 
Expression of 6xHis-tagged GFPm was carried out in leucine auxotrophic DH10B 
(Invitrogen) transformed with pQE-80L/GFPm, which was previously constructed by Yoo 
et al46.  Cultures of DH10B containing pQE-80L/GFPm were grown at 37oC to mid-log 
phase (OD600 ~ 0.8-1.0) in M9 minimal media (M9 salts, 0.2% glucose, 1 mM MgSO4, 0.1 
mM CaCl2, 35 mg/L Vitamin B) supplemented with all 20 canonical amino acids (each at 
40 mg/L), and ampicillin (200 µg/L).  Upon reaching mid-log phase, cells were pelleted 
and washed twice using 0.9% NaCl to deplete phenylalanine.  Cells were subsequently 
resuspended in M9 minimal media supplemented with 19 amino acids minus phenylalanine 
and plus 2 mM D,L-furanylalanine.  6xHis-tagged GFPm expression was induced by 
addition of 2 mM IPTG and carried out for 6 hr..  Cells were pelleted at 8000g and 4oC for 
10 minutes and frozen at -80C.  The cell pellet was lysed in 8 M urea with repeated freeze-
thaw cycles and 6xHis-tagged GFPm was purified under denaturing conditions using Ni-
NTA agarose.  Trypsin digests of purified 6xHis-tagged GFPm were subjected to MALDI-
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TOF MS with α-cyano-4-hydroxycinnamic acid as matrix.  An Applied Biosystems 
Voyager DE-PRO equipped with a 20-Hz nitrogen laser was used for all peptide analyses. 
 
Biotinylation of PheRS metabolically labeled with furanylalanine using maleimide Diels-
Alder Reaction 
Purified 6xHis-tagged, wild-type PheRS labeled with furanylalanine was treated with 2% 
β-mercaptoethanol at pH 7.8 and subsequently alkylated using 100 mM iodoacetamide, pH 
7.8 in the dark for 2 hr..  Acetone precipitation was performed to remove alkylating reagent 
and protein was re-solubilized with 1% SDS in PBS, pH 6.5.  Maleimide-PEG2-Biotin 
(Pierce) was added to a final concentration of 10 mM and reacted overnight at room 
temperature.  An additional acetone precipitation was performed and protein was re-
solubilized in 2% SDS loading buffer for visualization via western blot on low fluorescence 
nitrocellulose membrane (Amersham).  Blocking was performed with 5% w/v milk in 
PBST while washes were performed with PBST three times for 10 minutes.  Presence of 
6xHis-tagged, wild-type PheRS was visualized with Penta-His-AlexaFluor 647 (1:5000 
dilution, Qiagen); biotin was visualized with streptavidin conjugated AlexaFluor 488 
(1:2000 dilution, Invitrogen).  Visualization of fluorescently labeled antibodies used during 
western blotting was performed on a Typhoon Trio with appropriate laser and filter 
combinations.     
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Figure 4.1 
 
Structures of amino acids and probes discussed in this chapter. 1: Methionine; 2: S-
allyl-cysteine; 3: O-crotylserine; 4: S-allyl-homocysteine; 5: Phenylalanine; 6: p-
azidophenylalanine; 7: p-azidomethylphenylalanine; 8: p-aminomethylphenylalanine; 9: 3-
thienylalanine; 10: 3-furanylalanine; 111: DIBO-TAMRA; 12: Maleimide-PEG2-Biotin   
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Figure 4.2 
 
Structure of cucurbit[7]uril (Q7) and proposed binding of phenylalanine analogues.  
R groups at the para position of phenylalanine can range from halogens, alcohols, amines, 
t-butyl, carboxyl, phosphoryl, and azides.  This figure was reproduced from Logsdon et 
al16.   
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Figure 4.3 
a)   
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Figure 4.3 (cont) 
c)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Synthesis of S-allyl-homocysteine. a) Scheme of synthetic route to produce S-allyl-
homocysteine from L-homocysteine. b) 1H NMR spectra of purified S-allyl-homocysteine. 
c) 13C NMR spectra of purified S-allyl-homocysteine  
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Figure 4.4 
 
Overexpression of the wild-type MetRS enables quantitative replacement of 
methionine by S-allyl-homocysteine.  GFPrmAM expressed in methionine auxotrophs is 
subjected to trypsin digestion; peptides are analyzed by MALDI-TOF MS.  The peptide 
FEGMTIVNR is observed to have the correct expected mass when expressed in media 
containing all 20 canonical amino acids (top panel).   Expression of GFPrmAM with 
endogenous levels of the MetRS in media depleted of methionine and supplemented with 
S-allyl-homocysteine shows the presence of a second peak corresponding to the 26 Da 
increase caused by methionine replacement (middle panel).  Overexpression of the wild-
type MetRS enables near complete replacement of methionine by S-allyl-homocysteine, as 
marked by the shifting of the peak from 1066 to 1092 Da.    
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Figure 4.5 
 
In-gel detection of cell lysates modified with DIBO-TAMRA. Induction of wild-type 
PheRS and PheRS mutants is performed post-media shift in media containing 
phenylalanine or azide bearing phenylalanine analogues in phenylalanine auxotrophic 
KY14 cells.  Fluorescent signal in gel lanes arises from the attachment of DIBO-TAMRA 
to cellular proteins; DIBO-TAMRA undergoes strain-promoted azide-alkyne cycloaddition 
to azide analogues of phenylalanine if they are metabolically incorporated into proteins.    
No significant fluorescence is detected in lanes marked “20aa” for any overexpressed 
PheRS, due to the absence of metabolically incorporated azides.  Proteins labeled with p-
azidophenylalanine (N3F), used as a positive control for azide incorporation, are observed 
in cases where PheRS-A294G, PheRS-T251G, or PheRS-A294G&T251G are 
overexpressed.  In cases where p-azidomethylphenylalanine (N3CH2F) was added post-
media shift, overexpression of the wild-type PheRS does not permit incorporation; 
however, the three overexpressed PheRS mutants tested all show attachment of DIBO-
TAMRA to cellular proteins.    
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Figure 4.6
 
Furanylalanine incorporation is confirmed through MALDI-TOF MS analysis of 
purified 6xHis-tagged, wild-type PheRS.  The correct expected mass for the peptide 
FRPSYFPFTEPSAEVDVMGK is observed when the wild-type PheRS is expressed in 
phenylalanine auxotrophic KY14 in media containing all 20 amino acids (top panel).  
Replacement of phenylalanine with furanylalanine results in a mass shift of minus 10 Da.  
The peptide contains three phenylalanine residues and a distribution of four different peaks 
is observed (lower panel).         
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Figure 4.7 
 
Furanylalanine incorporation is observed in 6xHis-tagged GFPm expressed without 
overexpressed wild-type PheRS in a non-phenylalanine auxotroph.   The correct 
expected mass for the peptide DHMVLLEFVTAAGITHGMDELYKR is observed when 
6xHis-tagged GFPm is expressed in DH10B in media containing all 20 amino acids (top 
panel).  Approximately 10 percent of phenylalanine is replaced by furanylalanine, marked 
by the appearance of a new peak 10 Da smaller (lower panel).  
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Figure 4.8 
 
Diels-Alder reaction between wild-type PheRS metabolically labeled with 
furanylalanine and biotinylated maleimide probes.  Purified 6xHis-tagged, wild-type 
PheRS expressed in media containing furanylalanine was reduced and alkylated prior to 
overnight reaction with a biotinylated maleimide probe at room temperature.  Aliquots of 
the reaction mixture were run on SDS-PAGE and transferred to nitrocellulose membrane 
for western blotting.  Wild-type PheRS expressed in media containing the 20 canonical 
amino acids appears at correct molecular weight when probed using an antibody for penta-
his (left panel).  Biotin-PEG2-Maleimide (MW: 525.62) attachment to furanylalanine 
labeled wild-type PheRS results in an increase in molecular weight; wild-type PheRS 
contains a total of 20 possible phenylalanine positions that can be replaced by 
furanylalanine.  Incomplete alkylation enables reaction of maleimide with the lone free 
cysteine in wild-type PheRS resulting in biotinylation (middle panel).  Biotin is detected 
co-localized with anti-his signal for wild-type PheRS, confirming modification of 
furanylalanine with the maleimide probe.    
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Figure 4.9
 
 
Q7 binding to newly formed N-terminal aminomethylphenylalanine protects peptides 
from further exopeptidase degradation.   The peptide TGA(aminomethyl-
phenylalanine)M is treated with leucine aminopeptidase in the presence of 1mM Q7.  
Aliquots from the reaction mixture are removed an analyzed on HPLC.  Initial peptide 
undergoes a peak to peak conversion (top panel) to the Q7-stabilized dipeptide with N-
terminal aminomethylphenylalanine, which is the only species present in the reaction 
mixture after 38 hours of digestion (bottom panel).  The N-terminal 
aminomethylphenylalanine dipeptide bound to Q7 is confirmed through mass spectrometry.  
This is unpublished work from the Urbach Lab.  
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Concluding Remarks 
The amino acids described in this work have expanded artificial protein sequence space for 
researchers interested in doing residue-specific incorporation.  We have access to new 
chemical reactions through the incorporation of S-allyl-homocysteine, furanylalanine, and 
azidomethylphenylalanine; however, further work must be done to implement the 
chemistry in a practical manner.   
The growing complexity of unnatural amino acids often requires evolution of new 
aminoacyl-tRNA synthetases to enable their use in protein synthesis.  The discovery of the 
PraRS and propargylglycine pair could help to popularize cell-specific BONCAT 
approaches; the commercial availability and cost of propargylglycine should make 
propargylglycine attractive to researchers.  Another interesting aspect to propargylglycine 
is that it is a known natural product of various species of Streptomyces1,2 as well as other 
fungi3.  Although the biosynthetic pathways for propargylglycine are currently unknown, 
the ability to perform BONCAT without addition of any exogenous amino acids is an 
appealing proposition.   
Exploring artificial protein sequence space requires the incorporation of artificial amino 
acids into proteins, which can perturb protein structure and function; directed evolution is 
often required to recover the lost protein properties.  Expression of the homoisoleucine 
form of chloramphenicol acetyltransferase can be performed without any leucine remaining 
in the protein sequence, giving access to a new point in sequence space.  Using the 
homoisoleucine form of chloramphenicol acetyltransferase as a starting point, we can 
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continue to explore paths along the protein fitness landscape.  One could imagine that with 
sufficient directed evolution, we could arrive at a protein that can only function in the 
artificial protein sequence space.   
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